Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Maurizio Fava, M.D.

TitleSlater Family Professor of Psychiatry
InstitutionMassachusetts General Hospital
DepartmentPsychiatry
AddressMassachusetts General Hospital
Bulfinch 351
55 Fruit St
Boston MA 02114
Phone617/724-0838
Fax617/726-2688

 Biography 
 awards and honors
1988 - ACNP Travel Award
1988 - Edwin Dunlop Memorial Scholarship
1992 - Honorable Mention, APA/Wisniewski Young Psychiatrist Research Award
1994 - Young Investigator Award
1995 - Nomination HMS 1995 Award for Excellence in Mentoring
1996 - 2000Elected by Peers for Inclusion in Best Doctors in America
1996 - Honorable Mention, MGH Psychiatry Residency Class of 1996 Teaching Award
1996 - Third Place Winner, 1996 Dorfman Journal Paper Award
1997 - Hugo DeCuyper Lecture
1998 - 2000Nomination, HMS 2000 A. Clifford Barger Award for Excellence in Mentoring
1998 - Robert Kellner Lecture/Robert Kellner Research Symposium
1999 - Partners in Excellence Award
2004 - Nomination, HMS School Excellence in Mentoring Award
2005 - Outstanding Psychiatrist Award
2005 - Psychopharmacology Supervision Award
2006 - Distinguished Fellow Award
2006 - Peer Review Circle of Honor
2007 - Nomination, HMS Excellence in Mentoring Award

 Overview 
 overview
Narrative Report of Research, Teaching, and Clinical Contributions:
Dr. Fava is currently Vice Chair, Department of Psychiatry and Director of the Depression Clinical and Research Program (DCRP) at the Massachusetts General Hospital, as well as Professor of Psychiatry at Harvard Medical School. Director of the DCRP since 1990, Dr. Fava has expanded the program significantly, increasing the spending budget from $100,000 to over $3,000,000 per year. His research program’s impact on the field has also increased over the years, as reflected by over 50 presentations/year at National Meetings and over 30 original articles/year published in refereed journals. Under Dr. Fava’s direction, the DCRP has become one of the leading centers for the study of Unipolar Depressive Disorders in the country. Over the past 16 years, Dr. Fava has also been successful in obtaining more than $23,000,000 in funding for his program, as principal or co-principal investigator, from the National Institute of Health, other federal agencies, foundations, and pharmaceutical industries. Dr. Fava is also the co-Principal Investigator with Dr. A.John Rush of a $35,000,000 NIMH contract to study treatment-resistant depression, STAR*D, whose findings have been published in journals such NEJM and JAMA. In addition to his numerous clinical trials and studies in treatment resistant depression, Dr. Fava has contributed significantly to the field of psychiatric research in a number of other areas. He has identified a subtype of depressive disorder characterized by marked irritability and “anger attacks.” His innovative work has led to the discovery that these individuals present a blunted prolactin response to fenfluramine challenge, are more likely to have white matter hyperintensities, and may selectively respond to SSRIs. In addition, Dr. Fava has conducted important investigations on the role of folate deficiency in depression and on the efficacy in depression of one carbon cycle elements with putative antidepressant effects such as s-adenosyl-methionine (SAMe) and methylfolate. His pioneering work in this area has led to his current-R-01 grant on the efficacy of SAMe in major depressive disorder (MDD). He has conducted and published the first prospective, placebo-controlled study of discontinuation-emergent adverse events of the newer antidepressants and he has designed and developed a protocol for the first, large multicenter study on the effects of abrupt interruption of SSRI treatment. He has completed a large single-site study of bupropion augmentation of the nicotine patch in depressed smokers (as part of one of his previous R-01s) and he is currently the PI of a large U-01 aimed at developing new treatments for nicotine dependence. He has developed with Dr. David Schoenfeld a novel design to address the problem of excessive placebo response in antidepressant trials and to markedly reduce sample size requirements for trials (a patent has been filed on his behalf by Partners on this design). He has also been very interested in developing new instruments to measure the effects of antidepressants treatments, and several of his validated instruments (such as the DESS scale, SFQ scale, and the CPFQ scale) are being used by clinical investigators in the US and abroad. Because of his ability to collaborate very effectively with PCPs in research projects such as STAR*D, he has been recently named co-Medical Director of Partners Research and Education Program (PREP). With respect to his publications, Dr. Fava has authored or co-authored over 300 original articles published in refereed medical journals with international circulation. The citation impact of Dr. Fava’s work is extremely high, as his articles have been cited more than 3,000 times in the literature. He has also edited four books, and he has published more than 50 chapters and 450 abstracts.

Dr. Fava has an excellent track record as a teacher and has been very active in instructing and supervising psychiatric residents and fellows. Over the past 16 years, Dr. Fava has also trained and mentored a number of research fellows in his program, many of whom have continued to work in the area of psychiatric research following completion of their fellowship. Dr. Fava has also been the mentor/sponsor for several successful NARSAD, APA, and K Award fellowship applications (he is currently mentoring six K-23 Award recipients), and he has been nominated several times for the Harvard Medical School Award for Excellence in Mentoring. Over the past several years, he has organized and chaired numerous symposia and has served on many advisory panels for pharmaceutical companies. In addition, he has reviewed grant proposals and specific RFP concepts/contracts for the National Institute of Mental Health, the National Institute of Drug Abuse, and currently serves on an NCCAM study section. Dr. Fava is currently the co-director of the Psychopharmacology Course of the Harvard Medical School Department of Continuing Education, one of the most highly attended courses in the country, with approximately 800 participants each year. Dr. Fava has also lectured extensively, with over 250 presentations at national and international meetings and conferences.

He is considered an expert psychopharmacologist in the area of depression and frequently provides consultations to difficult cases referred to him from all over the world. He has been for the past nine years in charge of a large PO group practice of clinicians specialized in the treatment of patients with mood disorders, and his leadership skills have been key to the financial success of this group.


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Sarris J, Nierenberg AA, Schweitzer I, Alpert JE, Rosenbaum JF, Iovieno N, Covino J, Fava M, Mischoulon D. Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John's Wort in Major Depressive Disorder. J Clin Psychopharmacol. 2013 Dec; 33(6):827-30.
    View in: PubMed
  2. Pedrelli P, Nyer M, Holt D, Bakow BR, Fava M, Baer L, Cassiello C, Mulligan M, Cusin C, Farabaugh A. Correlates of irritability in college students with depressive symptoms. J Nerv Ment Dis. 2013 Nov; 201(11):953-8.
    View in: PubMed
  3. Toups MS, Myers AK, Wisniewski SR, Kurian B, Morris DW, Rush AJ, Fava M, Trivedi MH. Relationship between obesity and depression: characteristics and treatment outcomes with antidepressant medication. Psychosom Med. 2013 Nov; 75(9):863-72.
    View in: PubMed
  4. Rothschild AJ, Raskin J, Wang CN, Marangell LB, Fava M. The relationship between change in apathy and changes in cognition and functional outcomes in currently non-depressed SSRI-treated patients with major depressive disorder. Compr Psychiatry. 2014 Jan; 55(1):1-10.
    View in: PubMed
  5. Freeman MP, Walker R, Laughren TP, Miller KK, Fava M. Female reproductive life cycle and hormones: methodology to improve clinical trials. J Clin Psychiatry. 2013 Oct; 74(10):1018-21.
    View in: PubMed
  6. Kim B, Kang ES, Fava M, Mischoulon D, Soskin D, Yu BH, Lee D, Lee DY, Park HD, Jeon HJ. Follicle-stimulating hormone (FSH), current suicidal ideation and attempt in female patients with major depressive disorder. Psychiatry Res. 2013 Dec 30; 210(3):951-6.
    View in: PubMed
  7. Matthews JD, Siefert CJ, Blais MA, Park LT, Siefert CJ, Welch CA, Dubois CM, van Nieuwenhuizen AO, Rooney KO, Seabrook RC, Durham LE, Adams HC, Fava M. A Double-blind, Placebo-Controlled Study of the Impact of Galantamine on Anterograde Memory Impairment During Electroconvulsive Therapy. J ECT. 2013 Sep; 29(3):170-8.
    View in: PubMed
  8. Dording C, Cassiello C, King F, Pencina M, Fava M, Mischoulon D. The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression. Int Clin Psychopharmacol. 2013 Sep; 28(5):238-44.
    View in: PubMed
  9. Harte CB, Liverant GI, Sloan DM, Kamholz BW, Rosebrock LE, Fava M, Kaplan GB. Association between smoking and heart rate variability among individuals with depression. Ann Behav Med. 2013 Aug; 46(1):73-80.
    View in: PubMed
  10. Soskin DP, Holt DJ, Sacco GR, Fava M. Incentive salience: novel treatment strategies for major depression. CNS Spectr. 2013 Dec; 18(6):307-14.
    View in: PubMed
  11. Borsook D, Becerra L, Fava M. Use of functional imaging across clinical phases in CNS drug development. Transl Psychiatry. 2013; 3:e282.
    View in: PubMed
  12. Jeon HJ, Hong JP, Fava M, Mischoulon D, Nyer M, Inamori A, Sohn JH, Seong S, Cho MJ. Childhood parental death and lifetime suicide attempt of the opposite-gender offspring in a nationwide community sample of Korea. Suicide Life Threat Behav. 2013 Dec; 43(6):598-610.
    View in: PubMed
  13. Gilman SE, Breslau J, Trinh NH, Fava M, Murphy JM, Smoller JW. Dr Gilman and colleagues reply. J Clin Psychiatry. 2013 Jul; 74(7):741-3.
    View in: PubMed
  14. Cusin C, Iovieno N, Iosifescu DV, Nierenberg AA, Fava M, Rush AJ, Perlis RH. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013 Jul; 74(7):e636-41.
    View in: PubMed
  15. Nyer M, Farabaugh A, Fehling K, Soskin D, Holt D, Papakostas GI, Pedrelli P, Fava M, Pisoni A, Vitolo O, Mischoulon D. Relationship between sleep disturbance and depression, anxiety, and functioning in college students. Depress Anxiety. 2013 Sep; 30(9):873-80.
    View in: PubMed
  16. Yeung A, Slipp LE, Jacquart J, Fava M, Denninger JW, Benson H, Fricchione GL. The treatment of depressed chinese americans using qigong in a health care setting: a pilot study. Evid Based Complement Alternat Med. 2013; 2013:168784.
    View in: PubMed
  17. Ratti E, Bettica P, Alexander R, Archer G, Carpenter D, Evoniuk G, Gomeni R, Lawson E, Lopez M, Millns H, Rabiner EA, Trist D, Trower M, Zamuner S, Krishnan R, Fava M. Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. J Psychopharmacol. 2013 May; 27(5):424-34.
    View in: PubMed
  18. Cassano P, Chang T, Trinh NH, Baer L, Fava M, Mischoulon D. Differential impact of isolated psychotic symptoms on treatment outcome of major depressive disorder in the STAR*D cohort of Whites, Blacks and Latinos. J Affect Disord. 2013 Sep 5; 150(2):578-84.
    View in: PubMed
  19. Cardoos A, Inamori A, Sanacora G, Fava M, Mischoulon D. Delayed amnesic syndrome after riluzole use in major depressive disorder: a case report. Psychosomatics. 2013 Sep-Oct; 54(5):488-92.
    View in: PubMed
  20. Jeon HJ, Peng D, Chua HC, Srisurapanont M, Fava M, Bae JN, Man Chang S, Hong JP. Melancholic features and hostility are associated with suicidality risk in Asian patients with major depressive disorder. J Affect Disord. 2013 Jun; 148(2-3):368-74.
    View in: PubMed
  21. Vitali M, Tedeschini E, Mistretta M, Fehling K, Aceti F, Ceccanti M, Fava M. Adjunctive pregabalin in partial responders with major depressive disorder and residual anxiety. J Clin Psychopharmacol. 2013 Feb; 33(1):95-8.
    View in: PubMed
  22. Kornstein SG, Toups M, Rush AJ, Wisniewski SR, Thase ME, Luther J, Warden D, Fava M, Trivedi MH. Do Menopausal Status and Use of Hormone Therapy Affect Antidepressant Treatment Response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study. J Womens Health (Larchmt). 2013 Feb; 22(2):121-31.
    View in: PubMed
  23. Nyer M, Holt DJ, Pedrelli P, Fava M, Ameral V, Cassiello CF, Nock MK, Ross M, Hutchinson D, Farabaugh A. Factors that distinguish college students with depressive symptoms with and without suicidal thoughts. Ann Clin Psychiatry. 2013 Feb; 25(1):41-9.
    View in: PubMed
  24. Dording CM, Larocca RA, Hails KA, Vitolo OV, Wisniewski SR, Balasubramani GK, Trivedi M, Fava M, Mischoulon D. The effect of sildenafil on quality of life. Ann Clin Psychiatry. 2013 Feb; 25(1):3-10.
    View in: PubMed
  25. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013; 346:f288.
    View in: PubMed
  26. Doros G, Pencina M, Rybin D, Meisner A, Fava M. A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies. Stat Med. 2013 Jul 20; 32(16):2767-89.
    View in: PubMed
  27. Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012 Dec; 73(12):1541-7.
    View in: PubMed
  28. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M. l-Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials. Am J Psychiatry. 2012 Dec 1; 169(12):1267-74.
    View in: PubMed
  29. Witte J, Bentley K, Evins AE, Clain AJ, Baer L, Pedrelli P, Fava M, Mischoulon D. A randomized, controlled, pilot study of acamprosate added to escitalopram in adults with major depressive disorder and alcohol use disorder. J Clin Psychopharmacol. 2012 Dec; 32(6):787-96.
    View in: PubMed
  30. Gilman SE, Breslau J, Trinh NH, Fava M, Murphy JM, Smoller JW. Epidemiologic evidence concerning the bereavement exclusion in major depression. Arch Gen Psychiatry. 2012 Nov; 69(11):1179-81.
    View in: PubMed
  31. Yeung A, Lepoutre V, Wayne P, Yeh G, Slipp LE, Fava M, Denninger JW, Benson H, Fricchione GL. Tai chi treatment for depression in Chinese Americans: a pilot study. Am J Phys Med Rehabil. 2012 Oct; 91(10):863-70.
    View in: PubMed
  32. Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry. 2012 Oct; 169(10):1065-72.
    View in: PubMed
  33. Fava M, Targum SD, Nierenberg AA, Bleicher LS, Carter TA, Wedel PC, Hen R, Gage FH, Barlow C. An exploratory study of combination buspirone and melatonin SR in Major Depressive Disorder (MDD): A possible role for neurogenesis in drug discovery. J Psychiatr Res. 2012 Dec; 46(12):1553-63.
    View in: PubMed
  34. Perlis RH, Uher R, Perroud N, Fava M. Do suicidal thoughts or behaviors recur during a second antidepressant treatment trial? J Clin Psychiatry. 2012 Nov; 73(11):1439-42.
    View in: PubMed
  35. Nierenberg AA, Bentley KH, Farabaugh AH, Fava M, Deckersbach T. The absence of depressive symptoms is not the presence of wellness: Validation of the Clinical Positive Affect Scale. Aust N Z J Psychiatry. 2012 Dec; 46(12):1165-72.
    View in: PubMed
  36. Pedrelli P, Bentley K, Vitali M, Clain AJ, Nyer M, Fava M, Farabaugh AH. Compulsive use of alcohol among college students. Psychiatry Res. 2013 Jan 30; 205(1-2):95-102.
    View in: PubMed
  37. Farabaugh A, Alpert J, Wisniewski SR, Otto MW, Fava M, Baer L, Perlis R, Friedman E, Nyer M, Bitran S, Balasubramani GK, Inamori A, Trivedi M, Thase ME. Cognitive therapy for anxious depression in STAR(?)D: What have we learned? J Affect Disord. 2012 Dec 15; 142(1-3):213-8.
    View in: PubMed
  38. Yeung A, Feldman G, Pedrelli P, Hails K, Fava M, Reyes T, Mundt JC. The Quick Inventory of Depressive Symptomatology, clinician rated and self-report: a psychometric assessment in Chinese Americans with major depressive disorder. J Nerv Ment Dis. 2012 Aug; 200(8):712-5.
    View in: PubMed
  39. Hails K, Brill CD, Chang T, Yeung A, Fava M, Trinh NH. Cross-cultural aspects of depression management in primary care. Curr Psychiatry Rep. 2012 Aug; 14(4):336-44.
    View in: PubMed
  40. Kelley JM, Kaptchuk TJ, Cusin C, Lipkin S, Fava M. Open-label placebo for major depressive disorder: a pilot randomized controlled trial. Psychother Psychosom. 2012; 81(5):312-4.
    View in: PubMed
  41. Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry. 2012 Aug 1; 169(8):868-9.
    View in: PubMed
  42. Yeung AS, Jing Y, Brenneman SK, Chang TE, Baer L, Hebden T, Kalsekar I, McQuade RD, Kurlander J, Siebenaler J, Fava M. Clinical Outcomes in Measurement-based Treatment (Comet): a trial of depression monitoring and feedback to primary care physicians. Depress Anxiety. 2012 Oct; 29(10):865-73.
    View in: PubMed
  43. Krystal AD, McCall WV, Fava M, Joffe H, Soares CN, Huang H, Grinell T, Zummo J, Spalding W, Marshall R. Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity. Prim Care Companion CNS Disord. 2012; 14(4).
    View in: PubMed
  44. Soskin DP, Carl JR, Alpert J, Fava M. Antidepressant effects on emotional temperament: toward a biobehavioral research paradigm for major depressive disorder. CNS Neurosci Ther. 2012 Jun; 18(6):441-51.
    View in: PubMed
  45. Mischoulon D, Lamon-Fava S, Selhub J, Katz J, Papakostas GI, Iosifescu DV, Yeung AS, Dording CM, Farabaugh AH, Clain AJ, Baer L, Alpert JE, Nierenberg AA, Fava M. Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectr. 2012 Jun; 17(2):76-86.
    View in: PubMed
  46. Sung SC, Haley CL, Wisniewski SR, Fava M, Nierenberg AA, Warden D, Morris DW, Kurian BT, Trivedi MH, Rush AJ. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. J Clin Psychiatry. 2012 Jul; 73(7):967-76.
    View in: PubMed
  47. Gilman SE, Trinh NH, Smoller JW, Fava M, Murphy JM, Breslau J. Psychosocial stressors and the prognosis of major depression: a test of Axis IV. Psychol Med. 2013 Feb; 43(2):303-16.
    View in: PubMed
  48. Farabaugh A, Bitran S, Nyer M, Holt DJ, Pedrelli P, Shyu I, Hollon SD, Zisook S, Baer L, Busse W, Petersen TJ, Pender M, Tucker DD, Fava M. Depression and suicidal ideation in college students. Psychopathology. 2012; 45(4):228-34.
    View in: PubMed
  49. Mischoulon D, Alpert JE, Arning E, Bottiglieri T, Fava M, Papakostas GI. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J Clin Psychiatry. 2012 Jun; 73(6):843-8.
    View in: PubMed
  50. Mischoulon D, Brill CD, Ameral VE, Fava M, Yeung AS. A pilot study of acupuncture monotherapy in patients with major depressive disorder. J Affect Disord. 2012 Dec 10; 141(2-3):469-73.
    View in: PubMed
  51. Ripke S, Wray NR, Lewis CM, Hamilton SP, Weissman MM, Breen G, Byrne EM, Blackwood DH, Boomsma DI, Cichon S, Heath AC, Holsboer F, Lucae S, Madden PA, Martin NG, McGuffin P, Muglia P, Noethen MM, Penninx BP, Pergadia ML, Potash JB, Rietschel M, Lin D, Müller-Myhsok B, Shi J, Steinberg S, Grabe HJ, Lichtenstein P, Magnusson P, Perlis RH, Preisig M, Smoller JW, Stefansson K, Uher R, Kutalik Z, Tansey KE, Teumer A, Viktorin A, Barnes MR, Bettecken T, Binder EB, Breuer R, Castro VM, Churchill SE, Coryell WH, Craddock N, Craig IW, Czamara D, De Geus EJ, Degenhardt F, Farmer AE, Fava M, Frank J, Gainer VS, Gallagher PJ, Gordon SD, Goryachev S, Gross M, Guipponi M, Henders AK, Herms S, Hickie IB, Hoefels S, Hoogendijk W, Hottenga JJ, Iosifescu DV, Ising M, Jones I, Jones L, Jung-Ying T, Knowles JA, Kohane IS, Kohli MA, Korszun A, Landen M, Lawson WB, Lewis G, Macintyre D, Maier W, Mattheisen M, McGrath PJ, McIntosh A, McLean A, Middeldorp CM, Middleton L, Montgomery GM, Murphy SN, Nauck M, Nolen WA, Nyholt DR, O'Donovan M, Oskarsson H, Pedersen N, Scheftner WA, Schulz A, Schulze TG, Shyn SI, Sigurdsson E, Slager SL, Smit JH, Stefansson H, Steffens M, Thorgeirsson T, Tozzi F, Treutlein J, Uhr M, van den Oord EJ, Van Grootheest G, Völzke H, Weilburg JB, Willemsen G, Zitman FG, Neale B, Daly M, Levinson DF, Sullivan PF. A mega-analysis of genome-wide association studies for major depressive disorder. Mol Psychiatry. 2013 Apr; 18(4):497-511.
    View in: PubMed
  52. Castro VM, Gallagher PJ, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. BMJ Open. 2012; 2(2):e000544.
    View in: PubMed
  53. Davis LL, Pilkinton P, Wisniewski SR, Trivedi MH, Gaynes BN, Howland RH, Zisook S, Balasubramani GK, Fava M, Rush AJ. Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. Depress Anxiety. 2012 Feb; 29(2):111-22.
    View in: PubMed
  54. Dording CM, Dalton ED, Pencina MJ, Fava M, Mischoulon D. Comparison of academic and nonacademic sites in multi-center clinical trials. J Clin Psychopharmacol. 2012 Feb; 32(1):65-8.
    View in: PubMed
  55. Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom. 2012; 81(2):87-97.
    View in: PubMed
  56. Chang TE, Jing Y, Yeung AS, Brenneman SK, Kalsekar I, Hebden T, McQuade R, Baer L, Kurlander JL, Watkins AK, Siebenaler JA, Fava M. Effect of communicating depression severity on physician prescribing patterns: findings from the Clinical Outcomes in MEasurement-based Treatment (COMET) trial. Gen Hosp Psychiatry. 2012 Mar-Apr; 34(2):105-12.
    View in: PubMed
  57. Targum SD, Hassman H, Pinho M, Fava M. Development of a clinical global impression scale for fatigue. J Psychiatr Res. 2012 Mar; 46(3):370-4.
    View in: PubMed
  58. Cassano P, Fava M, Mischoulon D. Major depressive disorder with psychosis-like symptoms among Latinos. Psychiatr Serv. 2012; 63(5):482-7.
    View in: PubMed
  59. Gollan JK, Fava M, Kurian B, Wisniewski SR, Rush AJ, Daly E, Miyahara S, Trivedi MH. What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression? Depress Anxiety. 2012 Feb; 29(2):94-101.
    View in: PubMed
  60. Chan HN, Rush AJ, Nierenberg AA, Trivedi M, Wisniewski SR, Balasubramani GK, Friedman ES, Gaynes BN, Davis L, Morris D, Fava M. Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. Int J Neuropsychopharmacol. 2012 Nov; 15(10):1387-99.
    View in: PubMed
  61. Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ. Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. Acta Psychiatr Scand. 2012 Apr; 125(4):342-8.
    View in: PubMed
  62. McClintock SM, Husain MM, Bernstein IH, Wisniewski SR, Trivedi MH, Morris D, Alpert J, Warden D, Luther JF, Kornstein SG, Biggs MM, Fava M, Rush AJ. Assessing anxious features in depressed outpatients. Int J Methods Psychiatr Res. 2011 Dec; 20(4):e69-82.
    View in: PubMed
  63. Trinh NH, Bedoya CA, Chang TE, Flaherty K, Fava M, Yeung A. A study of a culturally focused psychiatric consultation service for Asian American and Latino American primary care patients with depression. BMC Psychiatry. 2011; 11:166.
    View in: PubMed
  64. Chen JA, Papakostas GI, Youn SJ, Baer L, Clain AJ, Fava M, Mischoulon D. Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. J Clin Psychiatry. 2011 Dec; 72(12):1669-76.
    View in: PubMed
  65. Zisook S, Lesser IM, Lebowitz B, Rush AJ, Kallenberg G, Wisniewski SR, Nierenberg AA, Fava M, Luther JF, Morris DW, Trivedi MH. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. J Clin Psychiatry. 2011 Oct; 72(10):1322-32.
    View in: PubMed
  66. Denninger JW, van Nieuwenhuizen AO, Wisniewski SR, Luther JF, Trivedi MH, Rush AJ, Gollan JK, Pizzagalli DA, Fava M. Changes in depressive symptoms and social functioning in the sequenced treatment alternatives to relieve depression study. J Nerv Ment Dis. 2011 Oct; 199(10):807-10.
    View in: PubMed
  67. Targum SD, Fava M. Fatigue as a residual symptom of depression. Innov Clin Neurosci. 2011 Oct; 8(10):40-3.
    View in: PubMed
  68. Evins AE, Pachas G, Mischoulon D, Urbanoski K, Carlini S, Sousa J, Bentley K, Rigotti NA, Nino-Gomez J, Loebl T, Janes AC, Kaufman MJ, Fava M. A double-blind, placebo-controlled trial of the NMDA glycine site antagonist, GW468816, for prevention of relapse to smoking in females. J Clin Psychopharmacol. 2011 Oct; 31(5):597-602.
    View in: PubMed
  69. Lesser IM, Zisook S, Gaynes BN, Wisniewski SR, Luther JF, Fava M, Khan A, McGrath P, Warden D, Rush AJ, Trivedi M. Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial. Psychiatr Serv. 2011 Oct; 62(10):1167-79.
    View in: PubMed
  70. Yeung A, Hails K, Chang T, Trinh NH, Fava M. A study of the effectiveness of telepsychiatry-based culturally sensitive collaborative treatment of depressed Chinese Americans. BMC Psychiatry. 2011; 11:154.
    View in: PubMed
  71. Mischoulon D, Witte J, Levy M, Papakostas GI, Pet LR, Hsieh WH, Pencina MJ, Ward S, Pollack MH, Fava M. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 2012 Mar; 73(3):353-7.
    View in: PubMed
  72. Tran P, Skolnick P, Czobor P, Huang NY, Bradshaw M, McKinney A, Fava M. Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. 2012 Jan; 46(1):64-71.
    View in: PubMed
  73. Friedman ES, Davis LL, Zisook S, Wisniewski SR, Trivedi MH, Fava M, Rush AJ. Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. Eur Neuropsychopharmacol. 2012 Mar; 22(3):183-99.
    View in: PubMed
  74. Gilman SE, Breslau J, Trinh NH, Fava M, Murphy JM, Smoller JW. Bereavement and the diagnosis of major depressive episode in the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2012 Feb; 73(2):208-15.
    View in: PubMed
  75. Fava M, Shelton RC, Zajecka JM. Evidence for the use of l-methylfolate combined with antidepressants in MDD. J Clin Psychiatry. 2011 Aug; 72(8):e25.
    View in: PubMed
  76. Farabaugh AH, Locascio JJ, Yap L, Fava M, Bitran S, Sousa JL, Growdon JH. Assessing depression and factors possibly associated with depression during the course of Parkinson's disease. Ann Clin Psychiatry. 2011 Aug; 23(3):171-7.
    View in: PubMed
  77. Desseilles M, Witte J, Chang TE, Iovieno N, Dording CM, Ashih H, Nyer M, Freeman MP, Fava M, Mischoulon D. Assessing the adequacy of past antidepressant trials: a clinician's guide to the antidepressant treatment response questionnaire. J Clin Psychiatry. 2011 Aug; 72(8):1152-4.
    View in: PubMed
  78. Janes AC, Smoller JW, David SP, Frederick BD, Haddad S, Basu A, Fava M, Evins AE, Kaufman MJ. Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. Drug Alcohol Depend. 2012 Jan 1; 120(1-3):7-13.
    View in: PubMed
  79. Bitran S, Farabaugh AH, Ameral VE, LaRocca RA, Clain AJ, Fava M, Mischoulon D. Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI. Int Clin Psychopharmacol. 2011 Jul; 26(4):206-12.
    View in: PubMed
  80. Perlis RH, Iosifescu DV, Castro VM, Murphy SN, Gainer VS, Minnier J, Cai T, Goryachev S, Zeng Q, Gallagher PJ, Fava M, Weilburg JB, Churchill SE, Kohane IS, Smoller JW. Using electronic medical records to enable large-scale studies in psychiatry: treatment resistant depression as a model. Psychol Med. 2012 Jan; 42(1):41-50.
    View in: PubMed
  81. Trivedi MH, Wisniewski SR, Morris DW, Fava M, Gollan JK, Warden D, Nierenberg AA, Gaynes BN, Husain MM, Luther JF, Zisook S, Rush AJ. Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry. 2011 Jun; 72(6):757-64.
    View in: PubMed
  82. Trivedi MH, Wisniewski SR, Morris DW, Fava M, Kurian BT, Gollan JK, Nierenberg AA, Warden D, Gaynes BN, Luther JF, Rush AJ. Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. J Clin Psychiatry. 2011 Jun; 72(6):765-74.
    View in: PubMed
  83. Sung SC, Dryman MT, Marks E, Shear MK, Ghesquiere A, Fava M, Simon NM. Complicated grief among individuals with major depression: prevalence, comorbidity, and associated features. J Affect Disord. 2011 Nov; 134(1-3):453-8.
    View in: PubMed
  84. Posternak MA, Baer L, Nierenberg AA, Fava M. Response rates to fluoxetine in subjects who initially show no improvement. J Clin Psychiatry. 2011 Jul; 72(7):949-54.
    View in: PubMed
  85. Bobo WV, Chen H, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Lesser IM, Kornstein SG, Wisniewski SR, Rush AJ, Shelton RC. Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. J Affect Disord. 2011 Oct; 133(3):467-76.
    View in: PubMed
  86. Mashhoon Y, Janes AC, Jensen JE, Prescot AP, Pachas G, Renshaw PF, Fava M, Evins AE, Kaufman MJ. Anterior cingulate proton spectroscopy glutamate levels differ as a function of smoking cessation outcome. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Aug 15; 35(7):1709-13.
    View in: PubMed
  87. Rush AJ, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JF, Husain MM, Cook IA, Shelton RC, Lesser IM, Kornstein SG, Wisniewski SR. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011 Jul; 168(7):689-701.
    View in: PubMed
  88. Trinh NH, Youn SJ, Sousa J, Regan S, Bedoya CA, Chang TE, Fava M, Yeung A. Using electronic medical records to determine the diagnosis of clinical depression. Int J Med Inform. 2011 Jul; 80(7):533-40.
    View in: PubMed
  89. Wickramaratne P, Gameroff MJ, Pilowsky DJ, Hughes CW, Garber J, Malloy E, King C, Cerda G, Sood AB, Alpert JE, Trivedi MH, Fava M, Rush AJ, Wisniewski S, Weissman MM. Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. Am J Psychiatry. 2011 Jun; 168(6):593-602.
    View in: PubMed
  90. Daly EJ, Trivedi MH, Fava M, Shelton R, Wisniewski SR, Morris DW, Stegman D, Preskorn SH, Rush AJ. The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. J Clin Psychopharmacol. 2011 Feb; 31(1):31-8.
    View in: PubMed
  91. Fava M, Dording CM, Baker RA, Mankoski R, Tran QV, Forbes RA, Eudicone JM, Owen R, Berman RM. Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion CNS Disord. 2011; 13(1).
    View in: PubMed
  92. Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, Roth T. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry. 2011 Jul; 72(7):914-28.
    View in: PubMed
  93. Perlis RH, Uher R, Ostacher M, Goldberg JF, Trivedi MH, Rush AJ, Fava M. Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. Arch Gen Psychiatry. 2011 Apr; 68(4):351-60.
    View in: PubMed
  94. Murphy JM, Gilman SE, Lesage A, Horton NJ, Rasic D, Trinh NH, Alamiri B, Sobol AM, Fava M, Smoller JW. Time trends in mortality associated with depression: findings from the Stirling County study. Can J Psychiatry. 2010 Dec; 55(12):776-83.
    View in: PubMed
  95. Blood AJ, Iosifescu DV, Makris N, Perlis RH, Kennedy DN, Dougherty DD, Kim BW, Lee MJ, Wu S, Lee S, Calhoun J, Hodge SM, Fava M, Rosen BR, Smoller JW, Gasic GP, Breiter HC. Microstructural abnormalities in subcortical reward circuitry of subjects with major depressive disorder. PLoS One. 2010; 5(11):e13945.
    View in: PubMed
  96. Pedrelli P, Bitran S, Shyu I, Baer L, Guidi J, Tucker DD, Vitali M, Fava M, Zisook S, Farabaugh AH. Compulsive alcohol use and other high-risk behaviors among college students. Am J Addict. 2011 Jan-Feb; 20(1):14-20.
    View in: PubMed
  97. Tedeschini E, Fava M, Papakostas GI. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. J Clin Psychiatry. 2011 Jan; 72(1):98-113.
    View in: PubMed
  98. Fava M, Schaefer K, Huang H, Wilson A, Iosifescu DV, Mischoulon D, Wessel TC. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry. 2011 Apr; 72(4):473-9.
    View in: PubMed
  99. Perlis RH, Huang J, Purcell S, Fava M, Rush AJ, Sullivan PF, Hamilton SP, McMahon FJ, Schulze TG, Schulze T, Potash JB, Zandi PP, Willour VL, Penninx BW, Boomsma DI, Vogelzangs N, Middeldorp CM, Rietschel M, Nöthen M, Cichon S, Gurling H, Bass N, McQuillin A, Hamshere M, Craddock N, Sklar P, Smoller JW. Genome-wide association study of suicide attempts in mood disorder patients. Am J Psychiatry. 2010 Dec; 167(12):1499-507.
    View in: PubMed
  100. Fava M, Mischoulon D. Evidence for folate in combination with antidepressants at initiation of therapy. J Clin Psychiatry. 2010 Nov; 71(11):e31.
    View in: PubMed
  101. Pedrelli P, Farabaugh AH, Zisook S, Tucker D, Rooney K, Katz J, Clain AJ, Petersen TJ, Fava M. Gender, depressive symptoms and patterns of alcohol use among college students. Psychopathology. 2011; 44(1):27-33.
    View in: PubMed
  102. Yeung A, Shyu I, Fisher L, Wu S, Yang H, Fava M. Culturally sensitive collaborative treatment for depressed chinese americans in primary care. Am J Public Health. 2010 Dec; 100(12):2397-402.
    View in: PubMed
  103. Chandler GM, Iosifescu DV, Pollack MH, Targum SD, Fava M. RESEARCH: Validation of the Massachusetts General Hospital Antidepressant Treatment History Questionnaire (ATRQ). CNS Neurosci Ther. 2010 Oct; 16(5):322-5.
    View in: PubMed
  104. Fava M. Using complementary and alternative medicines for depression. J Clin Psychiatry. 2010 Sep; 71(9):e24.
    View in: PubMed
  105. Huang J, Perlis RH, Lee PH, Rush AJ, Fava M, Sachs GS, Lieberman J, Hamilton SP, Sullivan P, Sklar P, Purcell S, Smoller JW. Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. Am J Psychiatry. 2010 Oct; 167(10):1254-63.
    View in: PubMed
  106. Janes AC, Pizzagalli DA, Richardt S, Frederick Bde B, Holmes AJ, Sousa J, Fava M, Evins AE, Kaufman MJ. Neural substrates of attentional bias for smoking-related cues: an FMRI study. Neuropsychopharmacology. 2010 Nov; 35(12):2339-45.
    View in: PubMed
  107. Yeung AS, Ameral VE, Chuzi SE, Fava M, Mischoulon D. A pilot study of acupuncture augmentation therapy in antidepressant partial and non-responders with major depressive disorder. J Affect Disord. 2011 Apr; 130(1-2):285-9.
    View in: PubMed
  108. Chang T, Fava M. The future of psychopharmacology of depression. J Clin Psychiatry. 2010 Aug; 71(8):971-5.
    View in: PubMed
  109. Farabaugh A, Sonawalla S, Johnson DP, Witte J, Papakostas GI, Goodness T, Clain A, Baer L, Mischoulon D, Fava M, Harley R. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment. Ann Clin Psychiatry. 2010 Aug; 22(3):166-71.
    View in: PubMed
  110. Dording CM, Mischoulon D, Goodness TM, Baer L, Clain A, Stewart JW, Matthews JD, McGrath PJ, Nierenberg AA, Fava M, Papakostas GI. Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: prevalence, response to treatment, and impact on short- and long-term treatment outcome. CNS Spectr. 2010 Aug; 15(8):515-21.
    View in: PubMed
  111. DeBattista C, Kinrys G, Hoffman D, Goldstein C, Zajecka J, Kocsis J, Teicher M, Potkin S, Preda A, Multani G, Brandt L, Schiller M, Iosifescu D, Fava M. The use of referenced-EEG (rEEG) in assisting medication selection for the treatment of depression. J Psychiatr Res. 2011 Jan; 45(1):64-75.
    View in: PubMed
  112. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry. 2010 Aug; 167(8):942-8.
    View in: PubMed
  113. Trinh NH, Shyu I, McGrath PJ, Clain A, Baer L, Fava M, Yeung A. Examining the role of race and ethnicity in relapse rates of major depressive disorder. Compr Psychiatry. 2011 Mar-Apr; 52(2):151-5.
    View in: PubMed
  114. Farabaugh AH, Bitran S, Witte J, Alpert J, Chuzi S, Clain AJ, Baer L, Fava M, McGrath PJ, Dording C, Mischoulon D, Papakostas GI. Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. Int Clin Psychopharmacol. 2010 Jul; 25(4):214-7.
    View in: PubMed
  115. Iovieno N, Dalton ED, Fava M, Mischoulon D. Second-tier natural antidepressants: review and critique. J Affect Disord. 2011 May; 130(3):343-57.
    View in: PubMed
  116. Fornaro M, Iovieno N, Clementi N, Boscaro M, Paggi F, Balercia G, Fava M, Papakostas GI. Diagnosis of co-morbid axis-I psychiatric disorders among women with newly diagnosed, untreated endocrine disorders. World J Biol Psychiatry. 2010 Dec; 11(8):991-6.
    View in: PubMed
  117. Sunderajan P, Gaynes BN, Wisniewski SR, Miyahara S, Fava M, Akingbala F, DeVeaugh-Geiss J, Rush AJ, Trivedi MH. Insomnia in patients with depression: a STAR*D report. CNS Spectr. 2010 Jun; 15(6):394-404.
    View in: PubMed
  118. Warden D, Trivedi MH, Wisniewski SR, Kurian B, Zisook S, Kornstein SG, Friedman ES, Miyahara S, Leuchter AF, Fava M, Rush AJ. Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report. J Clin Psychopharmacol. 2010 Jun; 30(3):259-66.
    View in: PubMed
  119. Freeman MP, Fava M, Lake J, Trivedi MH, Wisner KL, Mischoulon D. Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. J Clin Psychiatry. 2010 Jun; 71(6):669-81.
    View in: PubMed
  120. Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. J Clin Psychiatry. 2010 Jun; 71(6):682-8.
    View in: PubMed
  121. Kim BW, Kennedy DN, Lehár J, Lee MJ, Blood AJ, Lee S, Perlis RH, Smoller JW, Morris R, Fava M, Breiter HC. Recurrent, robust and scalable patterns underlie human approach and avoidance. PLoS One. 2010; 5(5):e10613.
    View in: PubMed
  122. Binder EB, Owens MJ, Liu W, Deveau TC, Rush AJ, Trivedi MH, Fava M, Bradley B, Ressler KJ, Nemeroff CB. Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. Arch Gen Psychiatry. 2010 Apr; 67(4):369-79.
    View in: PubMed
  123. Perlis RH, Smoller JW, Mysore J, Sun M, Gillis T, Purcell S, Rietschel M, Nöthen MM, Witt S, Maier W, Iosifescu DV, Sullivan P, Rush AJ, Fava M, Breiter H, Macdonald M, Gusella J. Prevalence of incompletely penetrant Huntington's disease alleles among individuals with major depressive disorder. Am J Psychiatry. 2010 May; 167(5):574-9.
    View in: PubMed
  124. Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. J Clin Psychiatry. 2010 May; 71(5):616-26.
    View in: PubMed
  125. Fava M. The possible antianxiety and mood-stabilizing effects of rufinamide. Psychother Psychosom. 2010; 79(3):194-5.
    View in: PubMed
  126. Tedeschini E, Fava M, Goodness TM, Papakostas GI. Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis. Eur Neuropsychopharmacol. 2010 Aug; 20(8):562-7.
    View in: PubMed
  127. Perlis RH, Ostacher M, Fava M, Nierenberg AA, Sachs GS, Rosenbaum JF. Assuring that double-blind is blind. Am J Psychiatry. 2010 Mar; 167(3):250-2.
    View in: PubMed
  128. Farabaugh A, Locascio JJ, Yap L, Growdon J, Fava M, Crawford C, Matthews J, McCutchen J, Buchin J, Pava J, Alpert JE. Cognitive-behavioral therapy for patients with Parkinson's disease and comorbid major depressive disorder. Psychosomatics. 2010 Mar-Apr; 51(2):124-9.
    View in: PubMed
  129. Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry. 2010 Mar; 11(2 Pt 2):300-7.
    View in: PubMed
  130. Yang H, Sinicropi-Yao L, Chuzi S, Youn SJ, Clain A, Baer L, Chen Y, McGrath PJ, Fava M, Papakostas GI. Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Ann Gen Psychiatry. 2010; 9:10.
    View in: PubMed
  131. Janes AC, Pizzagalli DA, Richardt S, deB Frederick B, Chuzi S, Pachas G, Culhane MA, Holmes AJ, Fava M, Evins AE, Kaufman MJ. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. Biol Psychiatry. 2010 Apr 15; 67(8):722-9.
    View in: PubMed
  132. Fava M. Switching treatments for complicated depression. J Clin Psychiatry. 2010 Feb; 71(2):e04.
    View in: PubMed
  133. Casamassima F, Huang J, Fava M, Sachs GS, Smoller JW, Cassano GB, Lattanzi L, Fagerness J, Stange JP, Perlis RH. Phenotypic effects of a bipolar liability gene among individuals with major depressive disorder. Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5; 153B(1):303-9.
    View in: PubMed
  134. Papakostas GI, Clain A, Ameral VE, Baer L, Brintz C, Smith WT, Londborg PD, Glaudin V, Painter JR, Fava M. Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol. 2010 Jan; 25(1):17-21.
    View in: PubMed
  135. Pedrelli P, Baer L, Losifescu DV, Fava M. Relationship between residual symptoms of depression and self-reported cognitive impairment. CNS Spectr. 2010 Jan; 15(1):46-51.
    View in: PubMed
  136. Janes AC, Frederick Bd, Richardt S, Burbridge C, Merlo-Pich E, Renshaw PF, Evins AE, Fava M, Kaufman MJ. Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence. Exp Clin Psychopharmacol. 2009 Dec; 17(6):365-73.
    View in: PubMed
  137. Miller KK, Perlis RH, Papakostas GI, Mischoulon D, Losifescu DV, Brick DJ, Fava M. Low-dose transdermal testosterone augmentation therapy improves depression severity in women. CNS Spectr. 2009 Dec; 14(12):688-94.
    View in: PubMed
  138. Davis LL, Wisniewski SR, Howland RH, Trivedi MH, Husain MM, Fava M, McGrath PJ, Balasubramani GK, Warden D, Rush AJ. Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend. 2010 Mar 1; 107(2-3):161-70.
    View in: PubMed
  139. Fava M. Augmentation and combination strategies for complicated depression. J Clin Psychiatry. 2009 Nov; 70(11):e40.
    View in: PubMed
  140. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009 Nov; 60(11):1439-45.
    View in: PubMed
  141. Montgomery SA, Fava M, Padmanabhan SK, Guico-Pabia CJ, Tourian KA. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Int Clin Psychopharmacol. 2009 Nov; 24(6):296-305.
    View in: PubMed
  142. Warden D, Trivedi MH, Wisniewski SR, Lesser IM, Mitchell J, Balasubramani GK, Fava M, Shores-Wilson K, Stegman D, Rush AJ. Identifying risk for attrition during treatment for depression. Psychother Psychosom. 2009; 78(6):372-9.
    View in: PubMed
  143. Gasic GP, Smoller JW, Perlis RH, Sun M, Lee S, Kim BW, Lee MJ, Holt DJ, Blood AJ, Makris N, Kennedy DK, Hoge RD, Calhoun J, Fava M, Gusella JF, Breiter HC. BDNF, relative preference, and reward circuitry responses to emotional communication. Am J Med Genet B Neuropsychiatr Genet. 2009 Sep 5; 150B(6):762-81.
    View in: PubMed
  144. Kashner TM, Trivedi MH, Wicker A, Fava M, Shores-Wilson K, Wisniewski SR, Rush AJ. Release bias in accessing medical records in clinical trials: a STAR*D report. Int J Methods Psychiatr Res. 2009 Sep; 18(3):147-58.
    View in: PubMed
  145. Farabaugh AH, Locascio JJ, Yap L, Weintraub D, McDonald WM, Agoston M, Alpert JE, Growdon J, Fava M. Pattern of depressive symptoms in Parkinson's disease. Psychosomatics. 2009 Sep-Oct; 50(5):448-54.
    View in: PubMed
  146. Bryan C, Songer T, Brooks MM, Rush AJ, Thase ME, Gaynes B, Balasubramani GK, Trivedi MH, Fava M, Wisniewski SR. The impact of diabetes on depression treatment outcomes. Gen Hosp Psychiatry. 2010 Jan-Feb; 32(1):33-41.
    View in: PubMed
  147. Leuchter AF, Cook IA, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, McCracken JT, Fava M, Iosifescu D, Greenwald S. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res. 2009 Sep 30; 169(2):124-31.
    View in: PubMed
  148. Kashner TM, Trivedi MH, Wicker A, Fava M, Wisniewski SR, Rush AJ. The impact of nonclinical factors on care use for patients with depression: a STAR*D report. CNS Neurosci Ther. 2009; 15(4):320-32.
    View in: PubMed
  149. Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res. 2009 Sep 30; 169(2):132-8.
    View in: PubMed
  150. Mischoulon D, Papakostas GI, Dording CM, Farabaugh AH, Sonawalla SB, Agoston AM, Smith J, Beaumont EC, Dahan LE, Alpert JE, Nierenberg AA, Fava M. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry. 2009 Dec; 70(12):1636-44.
    View in: PubMed
  151. Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, Nierenberg AA. STAR*D: revising conventional wisdom. CNS Drugs. 2009 Aug; 23(8):627-47.
    View in: PubMed
  152. Fava M, Wisniewski SR, Thase ME, Baker RA, Tran QV, Pikalov A, Yang H, Marcus RN, Berman RM. Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies. J Clin Psychopharmacol. 2009 Aug; 29(4):362-7.
    View in: PubMed
  153. Papakostas GI, Chuzi SE, Sousa JL, Fava M. 5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response. Eur Arch Psychiatry Clin Neurosci. 2010 Mar; 260(2):175-80.
    View in: PubMed
  154. Yang H, Chuzi S, Sinicropi-Yao L, Johnson D, Chen Y, Clain A, Baer L, McGrath PJ, Stewart JW, Fava M, Papakostas GI. Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Eur Arch Psychiatry Clin Neurosci. 2010 Mar; 260(2):145-50.
    View in: PubMed
  155. Iosifescu DV, Greenwald S, Devlin P, Mischoulon D, Denninger JW, Alpert JE, Fava M. Frontal EEG predictors of treatment outcome in major depressive disorder. Eur Neuropsychopharmacol. 2009 Nov; 19(11):772-7.
    View in: PubMed
  156. Fava M. Partial responders to antidepressant treatment: switching strategies. J Clin Psychiatry. 2009 Jul; 70(7):e24.
    View in: PubMed
  157. Kaufman MJ, Prescot AP, Ongur D, Evins AE, Barros TL, Medeiros CL, Covell J, Wang L, Fava M, Renshaw PF. Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. Psychiatry Res. 2009 Aug 30; 173(2):143-9.
    View in: PubMed
  158. Fava M, Asnis GM, Shrivastava R, Lydiard B, Bastani B, Sheehan D, Roth T. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol. 2009 Jun; 29(3):222-30.
    View in: PubMed
  159. Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, Miyahara S, Rush AJ. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010 Jan; 40(1):41-50.
    View in: PubMed
  160. Yeung A, Johnson DP, Trinh NH, Weng WC, Kvedar J, Fava M. Feasibility and effectiveness of telepsychiatry services for chinese immigrants in a nursing home. Telemed J E Health. 2009 May; 15(4):336-41.
    View in: PubMed
  161. Pizzagalli DA, Holmes AJ, Dillon DG, Goetz EL, Birk JL, Bogdan R, Dougherty DD, Iosifescu DV, Rauch SL, Fava M. Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder. Am J Psychiatry. 2009 Jun; 166(6):702-10.
    View in: PubMed
  162. Stewart JW, McGrath PJ, Fava M, Wisniewski SR, Zisook S, Cook I, Nierenberg AA, Trivedi MH, Balasubramani GK, Warden D, Lesser I, John Rush A. Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol. 2010 Feb; 13(1):15-30.
    View in: PubMed
  163. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr. 2009 Apr; 14(4):197-206.
    View in: PubMed
  164. Weiss AP, Guidi J, Fava M. Closing the efficacy-effectiveness gap: translating both the what and the how from randomized controlled trials to clinical practice. J Clin Psychiatry. 2009 Apr; 70(4):446-9.
    View in: PubMed
  165. Wisniewski SR, Rush AJ, Nierenberg AA, Gaynes BN, Warden D, Luther JF, McGrath PJ, Lavori PW, Thase ME, Fava M, Trivedi MH. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry. 2009 May; 166(5):599-607.
    View in: PubMed
  166. Perlis RH, Laje G, Smoller JW, Fava M, Rush AJ, McMahon FJ. Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients. Neuropsychopharmacology. 2009 Jun; 34(7):1819-28.
    View in: PubMed
  167. Fava M, Hwang I, Rush AJ, Sampson N, Walters EE, Kessler RC. The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. Mol Psychiatry. 2010 Aug; 15(8):856-67.
    View in: PubMed
  168. Kashner TM, Trivedi MH, Wicker A, Fava M, Greist JH, Mundt JC, Shores-Wilson K, Rush AJ, Wisniewski SR. Voice response system to measure healthcare costs: a STAR*D report. Am J Manag Care. 2009 Mar; 15(3):153-62.
    View in: PubMed
  169. Zisook S, Trivedi MH, Warden D, Lebowitz B, Thase ME, Stewart JW, Moutier C, Fava M, Wisniewski SR, Luther J, Rush AJ. Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. J Affect Disord. 2009 Sep; 117(1-2):63-73.
    View in: PubMed
  170. Fava M, Iosifescu DV, Pedrelli P, Baer L. Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychother Psychosom. 2009; 78(2):91-7.
    View in: PubMed
  171. Perlis RH, Fava M, Trivedi MH, Alpert J, Luther JF, Wisniewski SR, Rush AJ. Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. Acta Psychiatr Scand. 2009 Apr; 119(4):282-9.
    View in: PubMed
  172. Matthews JD, Siefert C, Dording C, Denninger JW, Park L, van Nieuwenhuizen AO, Sklarsky K, Hilliker S, Homberger C, Rooney K, Fava M. An open study of aripiprazole and escitalopram for psychotic major depressive disorder. J Clin Psychopharmacol. 2009 Feb; 29(1):73-6.
    View in: PubMed
  173. Feldman G, Harley R, Kerrigan M, Jacobo M, Fava M. Change in emotional processing during a dialectical behavior therapy-based skills group for major depressive disorder. Behav Res Ther. 2009 Apr; 47(4):316-21.
    View in: PubMed
  174. Nelson JC, Thase ME, Trivedi MH, Fava M, Han J, Van Tran Q, Pikalov A, Qi Y, Carlson BX, Marcus RN, Berman RM. Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry. 2009; 11(6):344-52.
    View in: PubMed
  175. Papakostas GI, Cooper-Kazaz R, Appelhof BC, Posternak MA, Johnson DP, Klibanski A, Lerer B, Fava M. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. Int Clin Psychopharmacol. 2009 Jan; 24(1):19-25.
    View in: PubMed
  176. Friedman ES, Wisniewski SR, Gilmer W, Nierenberg AA, Rush AJ, Fava M, Zisook S, Balasubramani GK, Trivedi MH. Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. Depress Anxiety. 2009; 26(7):612-21.
    View in: PubMed
  177. Kornstein SG, Fava M, Jiang Q, Tourian KA. Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo. Psychopharmacol Bull. 2009; 42(3):21-35.
    View in: PubMed
  178. Fava M, Mischoulon D. Folate in depression: efficacy, safety, differences in formulations, and clinical issues. J Clin Psychiatry. 2009; 70 Suppl 5:12-7.
    View in: PubMed
  179. Dording CM, Sinicropi-Yao L, Papakostas G, Matthews JD, Nierenberg AA, Fava M, Mischoulon D. The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder. Nord J Psychiatry. 2009; 63(5):420-5.
    View in: PubMed
  180. Morris DW, Trivedi MH, Fava M, Wisniewski SR, Balasubramani GK, Khan AY, Jain S, Rush AJ. Diurnal mood variation in outpatients with major depressive disorder. Depress Anxiety. 2009; 26(9):851-63.
    View in: PubMed
  181. Bryan C, Songer T, Brooks MM, Thase ME, Gaynes B, Klinkman M, Balasubramani GK, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. Do depressed patients with diabetes experience more side effects when treated with CitalopramThan their counterparts without diabetes? a STAR*D study. Prim Care Companion J Clin Psychiatry. 2009; 11(5):186-96.
    View in: PubMed
  182. Husain MM, Rush AJ, Wisniewski SR, McClintock SM, Fava M, Nierenberg AA, Davis L, Balasubramani GK, Young E, Albala AA, Trivedi MH. Family history of depression and therapeutic outcome: findings from STAR*D. J Clin Psychiatry. 2009 Feb; 70(2):185-95.
    View in: PubMed
  183. Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, Tran QV, Pikalov A, Carlson BX, Marcus RN, Berman RM. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry. 2008 Dec; 69(12):1928-36.
    View in: PubMed
  184. Evins AE, Culhane MA, Alpert JE, Pava J, Liese BS, Farabaugh A, Fava M. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. J Clin Psychopharmacol. 2008 Dec; 28(6):660-6.
    View in: PubMed
  185. Guidi J, Pender M, Hollon SD, Zisook S, Schwartz FH, Pedrelli P, Farabaugh A, Fava M, Petersen TJ. The prevalence of compulsive eating and exercise among college students: an exploratory study. Psychiatry Res. 2009 Jan 30; 165(1-2):154-62.
    View in: PubMed
  186. McGrath PJ, Khan AY, Trivedi MH, Stewart JW, Morris DW, Wisniewski SR, Miyahara S, Nierenberg AA, Fava M, Rush AJ. Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. J Clin Psychiatry. 2008 Dec; 69(12):1847-55.
    View in: PubMed
  187. Howland RH, Rush AJ, Wisniewski SR, Trivedi MH, Warden D, Fava M, Davis LL, Balasubramani GK, McGrath PJ, Berman SR. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. Drug Alcohol Depend. 2009 Jan 1; 99(1-3):248-60.
    View in: PubMed
  188. Pedrelli P, Feldman GC, Vorono S, Fava M, Petersen T. Dysfunctional attitudes and perceived stress predict depressive symptoms severity following antidepressant treatment in patients with chronic depression. Psychiatry Res. 2008 Dec 15; 161(3):302-8.
    View in: PubMed
  189. Makris N, Gasic GP, Kennedy DN, Hodge SM, Kaiser JR, Lee MJ, Kim BW, Blood AJ, Evins AE, Seidman LJ, Iosifescu DV, Lee S, Baxter C, Perlis RH, Smoller JW, Fava M, Breiter HC. Cortical thickness abnormalities in cocaine addiction--a reflection of both drug use and a pre-existing disposition to drug abuse? Neuron. 2008 Oct 9; 60(1):174-88.
    View in: PubMed
  190. Gelenberg AJ, Thase ME, Meyer RE, Goodwin FK, Katz MM, Kraemer HC, Potter WZ, Shelton RC, Fava M, Khan A, Trivedi MH, Ninan PT, Mann JJ, Bergeson S, Endicott J, Kocsis JH, Leon AC, Manji HK, Rosenbaum JF. The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry. 2008 Oct; 69(10):1513-28.
    View in: PubMed
  191. Foster CE, Webster MC, Weissman MM, Pilowsky DJ, Wickramaratne PJ, Talati A, Rush AJ, Hughes CW, Garber J, Malloy E, Cerda G, Kornstein SG, Alpert JE, Wisniewski SR, Trivedi MH, Fava M, King CA. Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms. J Clin Child Adolesc Psychol. 2008 Oct; 37(4):714-24.
    View in: PubMed
  192. Howland RH, Wilson MG, Kornstein SG, Clayton AH, Trivedi MH, Wohlreich MM, Fava M. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Ann Clin Psychiatry. 2008 Oct-Dec; 20(4):209-18.
    View in: PubMed
  193. Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009 Jan; 19(1):34-40.
    View in: PubMed
  194. Leuchter AF, Lesser IM, Trivedi MH, Rush AJ, Morris DW, Warden D, Fava M, Wisniewski SR, Luther JF, Perales M, Gaynes BN, Stewart JW. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J Psychiatr Pract. 2008 Sep; 14(5):271-80.
    View in: PubMed
  195. Mischoulon D, Fava M. Are nutritional supplements ready for prime time? J Clin Psychiatry. 2008 Sep; 69(9):1497-8.
    View in: PubMed
  196. Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Int Clin Psychopharmacol. 2008 Sep; 23(5):269-75.
    View in: PubMed
  197. Papakostas GI, McGrath P, Stewart J, Charles D, Chen Y, Mischoulon D, Dording C, Fava M. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Psychiatry Res. 2008 Oct 30; 161(1):116-20.
    View in: PubMed
  198. Young EA, Kornstein SG, Marcus SM, Harvey AT, Warden D, Wisniewski SR, Balasubramani GK, Fava M, Trivedi MH, John Rush A. Sex differences in response to citalopram: a STAR*D report. J Psychiatr Res. 2009 Feb; 43(5):503-11.
    View in: PubMed
  199. Gilmer WS, Gollan JK, Wisniewski SR, Howland RH, Trivedi MH, Miyahara S, Fleck J, Thase ME, Alpert JE, Nierenberg AA, Warden D, Fava M, Rush AJ. Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. J Clin Psychiatry. 2008 Aug; 69(8):1246-56.
    View in: PubMed
  200. Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, Nierenberg AA, Trivedi MH. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch Gen Psychiatry. 2008 Aug; 65(8):870-80.
    View in: PubMed
  201. Papakostas GI, Stahl SM, Krishen A, Seifert CA, Tucker VL, Goodale EP, Fava M. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. J Clin Psychiatry. 2008 Aug; 69(8):1287-92.
    View in: PubMed
  202. Perlis RH, Holt DJ, Smoller JW, Blood AJ, Lee S, Kim BW, Lee MJ, Sun M, Makris N, Kennedy DK, Rooney K, Dougherty DD, Hoge R, Rosenbaum JF, Fava M, Gusella J, Gasic GP, Breiter HC. Association of a polymorphism near CREB1 with differential aversion processing in the insula of healthy participants. Arch Gen Psychiatry. 2008 Aug; 65(8):882-92.
    View in: PubMed
  203. Fava M, Wiltse C, Walker D, Brecht S, Chen A, Perahia D. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. J Affect Disord. 2009 Mar; 113(3):263-71.
    View in: PubMed
  204. Candrian M, Schwartz F, Farabaugh A, Perlis RH, Ehlert U, Fava M. Personality disorders and perceived stress in major depressive disorder. Psychiatry Res. 2008 Aug 15; 160(2):184-91.
    View in: PubMed
  205. Pilowsky DJ, Wickramaratne P, Talati A, Tang M, Hughes CW, Garber J, Malloy E, King C, Cerda G, Sood AB, Alpert JE, Trivedi MH, Fava M, Rush AJ, Wisniewski S, Weissman MM. Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. Am J Psychiatry. 2008 Sep; 165(9):1136-47.
    View in: PubMed
  206. Mischoulon D, Best-Popescu C, Laposata M, Merens W, Murakami JL, Wu SL, Papakostas GI, Dording CM, Sonawalla SB, Nierenberg AA, Alpert JE, Fava M. A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder. Eur Neuropsychopharmacol. 2008 Sep; 18(9):639-45.
    View in: PubMed
  207. Pizzagalli DA, Iosifescu D, Hallett LA, Ratner KG, Fava M. Reduced hedonic capacity in major depressive disorder: evidence from a probabilistic reward task. J Psychiatr Res. 2008 Nov; 43(1):76-87.
    View in: PubMed
  208. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008 Apr; 28(2):156-65.
    View in: PubMed
  209. Nierenberg AA, Ostacher MJ, Huffman JC, Ametrano RM, Fava M, Perlis RH. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med. 2008 Apr; 50(4):428-36.
    View in: PubMed
  210. Papakostas GI, Homberger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. J Psychopharmacol. 2008 Nov; 22(8):843-8.
    View in: PubMed
  211. Iosifescu DV, Greenwald S, Devlin P, Perlis RH, Denninger JW, Alpert JE, Fava M. Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder. Acta Psychiatr Scand. 2008 Apr; 117(4):271-6.
    View in: PubMed
  212. Perlis RH, Moorjani P, Fagerness J, Purcell S, Trivedi MH, Fava M, Rush AJ, Smoller JW. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology. 2008 Nov; 33(12):2810-9.
    View in: PubMed
  213. Papakostas GI, Crawford CM, Scalia MJ, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Neuropsychobiology. 2007; 56(2-3):132-7.
    View in: PubMed
  214. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Balasubramani GK, McGrath PJ, Thase ME, Klinkman M, Nierenberg AA, Yates WR, Fava M. Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. J Gen Intern Med. 2008 May; 23(5):551-60.
    View in: PubMed
  215. Harley R, Sprich S, Safren S, Jacobo M, Fava M. Adaptation of dialectical behavior therapy skills training group for treatment-resistant depression. J Nerv Ment Dis. 2008 Feb; 196(2):136-43.
    View in: PubMed
  216. Iosifescu DV, Bolo NR, Nierenberg AA, Jensen JE, Fava M, Renshaw PF. Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry. 2008 Jun 15; 63(12):1127-34.
    View in: PubMed
  217. Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, Biggs MM, Zisook S, Leuchter A, Howland R, Warden D, Trivedi MH. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008 Mar; 165(3):342-51.
    View in: PubMed
  218. Dunner DL, Wilson M, Fava M, Kornstein S, Munoz R, O'Reardon J, Trivedi M, Wohlreich M. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. Depress Anxiety. 2008; 25(5):E1-8.
    View in: PubMed
  219. Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS, D'Souza DN. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms. Depress Anxiety. 2008; 25(7):E1-11.
    View in: PubMed
  220. Papakostas GI, Fava M. Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Dialogues Clin Neurosci. 2008; 10(4):439-51.
    View in: PubMed
  221. Petersen T, Perlis RH, Ticknor C, Lohr J, Solvason HB, O'Reardon JP, Wohlreich MM, Andreotti C, Wilson M, Fava M. Efficacy of duloxetine for the treatment of depression: relationship to most recent antidepressant trial. Psychopharmacol Bull. 2008; 41(1):34-45.
    View in: PubMed
  222. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008 Jan; 75(1):57-66.
    View in: PubMed
  223. Thase ME, Trivedi MH, Nelson JC, Fava M, Swanink R, Tran QV, Pikalov A, Yang H, Carlson BX, Marcus RN, Berman RM. Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry. 2008; 10(6):440-7.
    View in: PubMed
  224. Perahia DG, Quail D, Desaiah D, Corruble E, Fava M. Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry. 2008 Jan; 69(1):95-105.
    View in: PubMed
  225. Dording CM, Fisher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neurosci Ther. 2008; 14(3):182-91.
    View in: PubMed
  226. Targum SD, Pollack MH, Fava M. Redefining affective disorders: relevance for drug development. CNS Neurosci Ther. 2008; 14(1):2-9.
    View in: PubMed
  227. Kozel FA, Trivedi MH, Wisniewski SR, Miyahara S, Husain MM, Fava M, Lebowitz B, Zisook S, Rush AJ. Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. Am J Geriatr Psychiatry. 2008 Jan; 16(1):58-64.
    View in: PubMed
  228. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep. 2007 Dec; 9(6):449-59.
    View in: PubMed
  229. Davis LL, Frazier EC, Gaynes BN, Trivedi MH, Wisniewski SR, Fava M, Barkin J, Kashner TM, Shelton RC, Alpert JE, Rush AJ. Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort. J Clin Psychiatry. 2007 Dec; 68(12):1931-8.
    View in: PubMed
  230. Bryan CJ, Songer TJ, Brooks MM, Thase ME, Gaynes BN, Klinkman M, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: a STAR*D report. J Affect Disord. 2008 May; 108(1-2):113-20.
    View in: PubMed
  231. Mallinckrodt CH, Prakash A, Houston JP, Swindle R, Detke MJ, Fava M. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology. 2007; 56(2-3):73-85.
    View in: PubMed
  232. Papakostas GI, Fava M, Thase ME. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry. 2008 Apr 1; 63(7):699-704.
    View in: PubMed
  233. Yeung A, Fung F, Yu SC, Vorono S, Ly M, Wu S, Fava M. Validation of the Patient Health Questionnaire-9 for depression screening among Chinese Americans. Compr Psychiatry. 2008 Mar-Apr; 49(2):211-7.
    View in: PubMed
  234. Yeung A, Mischoulon D, Alpert J, Ma Y, Fava M. Acupuncture for major depressive disorder: has its efficacy been disproved? J Clin Psychiatry. 2007 Oct; 68(10):1617; author reply 1617-8.
    View in: PubMed
  235. Zisook S, Lesser I, Stewart JW, Wisniewski SR, Balasubramani GK, Fava M, Gilmer WS, Dresselhaus TR, Thase ME, Nierenberg AA, Trivedi MH, Rush AJ. Effect of age at onset on the course of major depressive disorder. Am J Psychiatry. 2007 Oct; 164(10):1539-46.
    View in: PubMed
  236. Candrian M, Farabaugh A, Pizzagalli DA, Baer L, Fava M. Perceived stress and cognitive vulnerability mediate the effects of personality disorder comorbidity on treatment outcome in major depressive disorder: a path analysis study. J Nerv Ment Dis. 2007 Sep; 195(9):729-37.
    View in: PubMed
  237. Fraguas R, Iosifescu DV, Alpert J, Wisniewski SR, Barkin JL, Trivedi MH, Rush AJ, Fava M. Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study. Psychosomatics. 2007 Sep-Oct; 48(5):418-25.
    View in: PubMed
  238. Morris DW, Rush AJ, Jain S, Fava M, Wisniewski SR, Balasubramani GK, Khan AY, Trivedi MH. Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. J Clin Psychiatry. 2007 Sep; 68(9):1339-47.
    View in: PubMed
  239. Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, Nierenberg AA, Fava M, Wong KK. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol. 2008 Mar; 18(3):230-3.
    View in: PubMed
  240. Matthews JD, Blais M, Park L, Welch C, Baity M, Murakami J, Sklarsky K, Homberger C, Fava M. The impact of galantamine on cognition and mood during electroconvulsive therapy: a pilot study. J Psychiatr Res. 2008 Jun; 42(7):526-31.
    View in: PubMed
  241. Warden D, Trivedi MH, Wisniewski SR, Davis L, Nierenberg AA, Gaynes BN, Zisook S, Hollon SD, Balasubramani GK, Howland R, Fava M, Stewart JW, Rush AJ. Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. Am J Psychiatry. 2007 Aug; 164(8):1189-97.
    View in: PubMed
  242. Husain MM, Rush AJ, Trivedi MH, McClintock SM, Wisniewski SR, Davis L, Luther JF, Zisook S, Fava M. Pain in depression: STAR*D study findings. J Psychosom Res. 2007 Aug; 63(2):113-22.
    View in: PubMed
  243. Young EA, Kornstein SG, Harvey AT, Wisniewski SR, Barkin J, Fava M, Trivedi MH, Rush AJ. Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. Psychoneuroendocrinology. 2007 Aug; 32(7):843-53.
    View in: PubMed
  244. Papakostas GI, Charles D, Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry. 2007 Jul 13; 1-8.
    View in: PubMed
  245. Hu XZ, Rush AJ, Charney D, Wilson AF, Sorant AJ, Papanicolaou GJ, Fava M, Trivedi MH, Wisniewski SR, Laje G, Paddock S, McMahon FJ, Manji H, Lipsky RH. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry. 2007 Jul; 64(7):783-92.
    View in: PubMed
  246. Petersen T, Fava M, Alpert JE, Vorono S, Sanders KM, Mischoulon D. Does psychiatry residency training reflect the "real world" of psychiatry practice? A survey of residency graduates. Acad Psychiatry. 2007 Jul-Aug; 31(4):281-9.
    View in: PubMed
  247. Fava M, Thase ME, DeBattista C, Doghramji K, Arora S, Hughes RJ. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann Clin Psychiatry. 2007 Jul-Sep; 19(3):153-9.
    View in: PubMed
  248. Fava M, Martinez JM, Greist J, Marangell LB, Brown E, Chen L, Wohlreich MM. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study. Ann Clin Psychiatry. 2007 Jul-Sep; 19(3):187-95.
    View in: PubMed
  249. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007 Dec 1; 62(11):1217-27.
    View in: PubMed
  250. Perlis RH, Purcell S, Fava M, Fagerness J, Rush AJ, Trivedi MH, Smoller JW. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry. 2007 Jun; 64(6):689-97.
    View in: PubMed
  251. Papakostas GI, Shelton RC, Smith J, Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry. 2007 Jun; 68(6):826-31.
    View in: PubMed
  252. Thase ME, Friedman ES, Biggs MM, Wisniewski SR, Trivedi MH, Luther JF, Fava M, Nierenberg AA, McGrath PJ, Warden D, Niederehe G, Hollon SD, Rush AJ. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007 May; 164(5):739-52.
    View in: PubMed
  253. Wisniewski SR, Fava M, Trivedi MH, Thase ME, Warden D, Niederehe G, Friedman ES, Biggs MM, Sackeim HA, Shores-Wilson K, McGrath PJ, Lavori PW, Miyahara S, Rush AJ. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry. 2007 May; 164(5):753-60.
    View in: PubMed
  254. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Eur Psychiatry. 2007 Oct; 22(7):444-7.
    View in: PubMed
  255. Lesser IM, Leuchter AF, Trivedi MH, Davis LL, Wisniewski SR, Balasubramani GK, Fava M, Rush AJ. Insured and non-insured depressed outpatients: how do they compare? Ann Clin Psychiatry. 2007 Apr-Jun; 19(2):73-82.
    View in: PubMed
  256. Fraguas R, Marci C, Fava M, Iosifescu DV, Bankier B, Loh R, Dougherty DD. Autonomic reactivity to induced emotion as potential predictor of response to antidepressant treatment. Psychiatry Res. 2007 May 30; 151(1-2):169-72.
    View in: PubMed
  257. Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Balasubramani GK, Spencer DC, Petersen T, Klinkman M, Warden D, Nicholas L, Fava M. Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. Ann Fam Med. 2007 Mar-Apr; 5(2):126-34.
    View in: PubMed
  258. Wisniewski SR, Rush AJ, Bryan C, Shelton R, Trivedi MH, Marcus S, Husain MM, Hollon SD, Fava M. Comparison of quality of life measures in a depressed population. J Nerv Ment Dis. 2007 Mar; 195(3):219-25.
    View in: PubMed
  259. Nierenberg AA, Katz J, Fava M. A critical overview of the pharmacologic management of treatment-resistant depression. Psychiatr Clin North Am. 2007 Mar; 30(1):13-29.
    View in: PubMed
  260. Moore HK, Wohlreich MM, Wilson MG, Mundt JC, Fava M, Mallinckrodt CH, Greist JH. Using daily interactive voice response assessments: to measure onset of symptom improvement with duloxetine. Psychiatry (Edgmont). 2007 Mar; 4(3):30-8.
    View in: PubMed
  261. Krystal A, Fava M, Rubens R, Wessel T, Caron J, Wilson P, Roth T, McCall WV. Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med. 2007 Feb 15; 3(1):48-55.
    View in: PubMed
  262. Perlis RH, Purcell S, Fagerness J, Cusin C, Yamaki L, Fava M, Smoller JW. Clinical and genetic dissection of anger expression and CREB1 polymorphisms in major depressive disorder. Biol Psychiatry. 2007 Sep 1; 62(5):536-40.
    View in: PubMed
  263. Fava M, Targum SD. Augmentation and combination strategies to treat the residual symptoms of major depressive disorder. Psychiatry (Edgmont). 2007 Feb; 4(2):16-8.
    View in: PubMed
  264. Peterson TJ, Feldman G, Harley R, Fresco DM, Graves L, Holmes A, Bogdan R, Papakostas GI, Bohn L, Lury RA, Fava M, Segal ZV. Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment. J Consult Clin Psychol. 2007 Feb; 75(1):145-53.
    View in: PubMed
  265. Papakostas GI, Hallett LA, Smith J, Tossani E, Mascarini A, Burns AM, Birnbaum RJ, Fava M, Alpert JE. A survey of five antidepressant properties influencing clinician's treatment choices in MDD. Neuropsychiatr Dis Treat. 2007 Feb; 3(1):169-72.
    View in: PubMed
  266. Iosifescu DV, Renshaw PF, Dougherty DD, Lyoo IK, Lee HK, Fraguas R, Cassano P, Nierenberg AA, Fava M. Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities. J Nerv Ment Dis. 2007 Feb; 195(2):175-8.
    View in: PubMed
  267. Farabaugh A, Mischoulon D, Schwartz F, Pender M, Fava M, Alpert J. Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD. Depress Anxiety. 2007; 24(6):433-9.
    View in: PubMed
  268. Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM, Rosenbaum JF, Perlis RH. Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications. J Clin Psychiatry. 2007 Jan; 68(1):52-7.
    View in: PubMed
  269. Fava M. Augmenting antidepressants with folate: a clinical perspective. J Clin Psychiatry. 2007; 68 Suppl 10:4-7.
    View in: PubMed
  270. Fava M. The combination of buspirone and bupropion in the treatment of depression. Psychother Psychosom. 2007; 76(5):311-2.
    View in: PubMed
  271. Perlis RH, Beasley CM, Wines JD, Tamura RN, Cusin C, Shear D, Amsterdam J, Quitkin F, Strong RE, Rosenbaum JF, Fava M. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom. 2007; 76(1):40-6.
    View in: PubMed
  272. Fraguas R, Iosifescu DV, Bankier B, Perlis R, Clementi-Craven N, Alpert J, Fava M. Major depressive disorder with anger attacks and cardiovascular risk factors. Int J Psychiatry Med. 2007; 37(1):99-111.
    View in: PubMed
  273. Yates WR, Mitchell J, John Rush A, Trivedi M, Wisniewski SR, Warden D, Bryan C, Fava M, Husain MM, Gaynes BN. Clinical features of depression in outpatients with and without co-occurring general medical conditions in STAR*D: confirmatory analysis. Prim Care Companion J Clin Psychiatry. 2007; 9(1):7-15.
    View in: PubMed
  274. Papakostas GI, Petersen T, Homberger CH, Green CH, Smith J, Alpert JE, Fava M. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder. Ann Clin Psychiatry. 2007 Jan-Mar; 19(1):5-8.
    View in: PubMed
  275. Papakostas GI, Perlis RH, Seifert C, Fava M. Antidepressant dose reduction and the risk of relapse in major depressive disorder. Psychother Psychosom. 2007; 76(5):266-70.
    View in: PubMed
  276. Papakostas GI, Petersen T, Sklarsky KG, Nierenberg AA, Alpert JE, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res. 2007 Jan 15; 149(1-3):195-200.
    View in: PubMed
  277. Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiatry. 2006 Nov; 67(11):1754-9.
    View in: PubMed
  278. Fava M, Rush AJ, Alpert JE, Carmin CN, Balasubramani GK, Wisniewski SR, Trivedi MH, Biggs MM, Shores-Wilson K. What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. Can J Psychiatry. 2006 Nov; 51(13):823-35.
    View in: PubMed
  279. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov; 163(11):1905-17.
    View in: PubMed
  280. Papakostas GI, Fava M. A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Can J Psychiatry. 2006 Oct; 51(12):783-90.
    View in: PubMed
  281. Yeung A, Yu SC, Fung F, Vorono S, Fava M. Recognizing and engaging depressed Chinese Americans in treatment in a primary care setting. Int J Geriatr Psychiatry. 2006 Sep; 21(9):819-23.
    View in: PubMed
  282. McGrath PJ, Stewart JW, Quitkin FM, Chen Y, Alpert JE, Nierenberg AA, Fava M, Cheng J, Petkova E. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006 Sep; 163(9):1542-8.
    View in: PubMed
  283. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wilson K, Rush AJ. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006 Sep; 163(9):1519-30; quiz 1665.
    View in: PubMed
  284. McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, Thase ME, Davis L, Biggs MM, Shores-Wilson K, Luther JF, Niederehe G, Warden D, Rush AJ. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006 Sep; 163(9):1531-41; quiz 1666.
    View in: PubMed
  285. Trivedi MH, Fava M, Marangell LB, Osser DN, Shelton RC. Use of treatment algorithms for depression. J Clin Psychiatry. 2006 Sep; 67(9):1458-65.
    View in: PubMed
  286. Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006 Dec 15; 60(12):1350-5.
    View in: PubMed
  287. Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF, Niederehe G, Ritz L, Trivedi MH. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006 Jul; 163(7):1161-72.
    View in: PubMed
  288. Denninger JW, Papakostas GI, Mahal Y, Merens W, Alpert JE, Nierenberg AA, Yeung A, Fava M. Somatic symptoms in outpatients with major depressive disorder treated with fluoxetine. Psychosomatics. 2006 Jul-Aug; 47(4):348-52.
    View in: PubMed
  289. Davis LL, Frazier E, Husain MM, Warden D, Trivedi M, Fava M, Cassano P, McGrath PJ, Balasubramani GK, Wisniewski SR, Rush AJ. Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. Am J Addict. 2006 Jul-Aug; 15(4):278-85.
    View in: PubMed
  290. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, Regier DA, Rosenbaum JF, Ray O, Schatzberg AF. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006 Sep; 31(9):1841-53.
    View in: PubMed
  291. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2007 Jan; 17(1):32-6.
    View in: PubMed
  292. Farabaugh AH, Sonawalla SB, Fava M, Pedrelli P, Papakostas GI, Schwartz F, Mischoulon D. Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis. Hum Psychopharmacol. 2006 Jun; 21(4):221-5.
    View in: PubMed
  293. Kessler RC, Coccaro EF, Fava M, Jaeger S, Jin R, Walters E. The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2006 Jun; 63(6):669-78.
    View in: PubMed
  294. Papakostas GI, Miller KK, Petersen T, Sklarsky KG, Hilliker SE, Klibanski A, Fava M. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun; 67(6):952-7.
    View in: PubMed
  295. Nierenberg AA, Trivedi MH, Fava M, Biggs MM, Shores-Wilson K, Wisniewski SR, Balasubramani GK, Rush AJ. Family history of mood disorder and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. J Psychiatr Res. 2007 Apr-Jun; 41(3-4):214-21.
    View in: PubMed
  296. Fava M, Detke MJ, Balestrieri M, Wang F, Raskin J, Perahia D. Management of depression relapse: re-initiation of duloxetine treatment or dose increase. J Psychiatr Res. 2006 Jun; 40(4):328-36.
    View in: PubMed
  297. Fava M. Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol. 2006 May; 20(3 Suppl):29-34.
    View in: PubMed
  298. Simon NM, Smoller JW, McNamara KL, Maser RS, Zalta AK, Pollack MH, Nierenberg AA, Fava M, Wong KK. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry. 2006 Sep 1; 60(5):432-5.
    View in: PubMed
  299. Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006 Jun 1; 59(11):1052-60.
    View in: PubMed
  300. Khan AY, Carrithers J, Preskorn SH, Lear R, Wisniewski SR, John Rush A, Stegman D, Kelley C, Kreiner K, Nierenberg AA, Fava M. Clinical and demographic factors associated with DSM-IV melancholic depression. Ann Clin Psychiatry. 2006 Apr-Jun; 18(2):91-8.
    View in: PubMed
  301. Papakostas GI, Petersen TJ, Perlis RH, Judy AE, Burns AM, Alpert JE, Birnbaum RJ, Fava M. A survey of antidepressant prescribing practices in major depression with comorbid attention-deficit hyperactivity disorder. J Clin Psychopharmacol. 2006 Apr; 26(2):216-8.
    View in: PubMed
  302. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006 Mar 23; 354(12):1231-42.
    View in: PubMed
  303. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006 Mar 23; 354(12):1243-52.
    View in: PubMed
  304. Weissman MM, Pilowsky DJ, Wickramaratne PJ, Talati A, Wisniewski SR, Fava M, Hughes CW, Garber J, Malloy E, King CA, Cerda G, Sood AB, Alpert JE, Trivedi MH, Rush AJ. Remissions in maternal depression and child psychopathology: a STAR*D-child report. JAMA. 2006 Mar 22; 295(12):1389-98.
    View in: PubMed
  305. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006 May; 78(5):804-14.
    View in: PubMed
  306. Fava M, Nurnberg HG, Seidman SN, Holloway W, Nicholas S, Tseng LJ, Stecher VJ. Efficacy and safety of sildenafil in men with serotonergic antidepressant-associated erectile dysfunction: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2006 Feb; 67(2):240-6.
    View in: PubMed
  307. Thase ME, Fava M, DeBattista C, Arora S, Hughes RJ. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr. 2006 Feb; 11(2):93-102.
    View in: PubMed
  308. Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J Clin Psychopharmacol. 2006 Feb; 26(1):56-60.
    View in: PubMed
  309. Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Perlis RH, Papakostas GI, Nierenberg AA, Fava M. Brain white-matter hyperintensities and treatment outcome in major depressive disorder. Br J Psychiatry. 2006 Feb; 188:180-5.
    View in: PubMed
  310. Hazen E, Fava M. Successful treatment with duloxetine in a case of treatment refractory bulimia nervosa: a case report. J Psychopharmacol. 2006 Sep; 20(5):723-4.
    View in: PubMed
  311. Pilowsky DJ, Wickramaratne PJ, Rush AJ, Hughes CW, Garber J, Malloy E, King CA, Cerda G, Sood AB, Alpert JE, Wisniewski SR, Trivedi MH, Talati A, Carlson MM, Liu HH, Fava M, Weissman MM. Children of currently depressed mothers: a STAR*D ancillary study. J Clin Psychiatry. 2006 Jan; 67(1):126-36.
    View in: PubMed
  312. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry. 2006; 67 Suppl 4:27-30.
    View in: PubMed
  313. Trivedi MH, Fava M, Marangell LB, Osser DN, Shelton RC. Use of treatment algorithms for depression. Prim Care Companion J Clin Psychiatry. 2006; 8(5):291-8.
    View in: PubMed
  314. Dougherty DD, Bonab AA, Ottowitz WE, Livni E, Alpert NM, Rauch SL, Fava M, Fischman AJ. Decreased striatal D1 binding as measured using PET and [11C]SCH 23,390 in patients with major depression with anger attacks. Depress Anxiety. 2006; 23(3):175-7.
    View in: PubMed
  315. Petersen T, Iosifescu DV, Papakostas GI, Shear DL, Fava M. Clinical characteristics of depressed patients with comorbid diabetes mellitus. Int Clin Psychopharmacol. 2006 Jan; 21(1):43-7.
    View in: PubMed
  316. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006 Jan; 163(1):28-40.
    View in: PubMed
  317. Harley R, Petersen T, Scalia M, Papakostas GI, Farabaugh A, Fava M. Problem-solving ability and comorbid personality disorders in depressed outpatients. Depress Anxiety. 2006; 23(8):496-501.
    View in: PubMed
  318. Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry. 2006; 67 Suppl 4:14-21.
    View in: PubMed
  319. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006; 75(3):139-53.
    View in: PubMed
  320. Papakostas GI, Worthington JJ, Iosifescu DV, Kinrys G, Burns AM, Fisher LB, Homberger CH, Mischoulon D, Fava M. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety. 2006; 23(3):178-81.
    View in: PubMed
  321. Iosifescu DV, Papakostas GI, Lyoo IK, Lee HK, Renshaw PF, Alpert JE, Nierenberg A, Fava M. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). Psychiatry Res. 2005 Dec 30; 140(3):291-9.
    View in: PubMed
  322. Fraguas R, Papakostas GI, Mischoulon D, Bottiglieri T, Alpert J, Fava M. Anger attacks in major depressive disorder and serum levels of homocysteine. Biol Psychiatry. 2006 Aug 1; 60(3):270-4.
    View in: PubMed
  323. Wohlreich MM, Martinez JM, Mallinckrodt CH, Prakash A, Watkin JG, Fava M. An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. J Clin Psychopharmacol. 2005 Dec; 25(6):552-60.
    View in: PubMed
  324. Papakostas GI, Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Alpert JE, Nierenberg AA, Fava M. Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). Psychiatry Res. 2005 Dec 30; 140(3):301-7.
    View in: PubMed
  325. Farabaugh A, Ongur D, Fava M, Hamill SK, Burns AM, Alpert J. Personality disorders and the trimensional personality questionnaire factors in major depressive disorder. J Nerv Ment Dis. 2005 Nov; 193(11):747-50.
    View in: PubMed
  326. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Oct; 66(10):1326-30.
    View in: PubMed
  327. Wohlreich MM, Mallinckrodt CH, Watkin JG, Wilson MG, Greist JH, Delgado PL, Fava M. Immediate switching of antidepressant therapy: results from a clinical trial of duloxetine. Ann Clin Psychiatry. 2005 Oct-Dec; 17(4):259-68.
    View in: PubMed
  328. Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Murck H, Rosenbaum JF. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7.
    View in: PubMed
  329. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC, Shores-Wilson K, Biggs MM, Woo A, Nierenberg AA, Fava M. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006 Mar 15; 59(6):493-501.
    View in: PubMed
  330. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, Nierenberg AA, Fava M. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med. 2005 Sep-Oct; 67(5):703-6.
    View in: PubMed
  331. Iosifescu DV, Nierenberg AA, Mischoulon D, Perlis RH, Papakostas GI, Ryan JL, Alpert JE, Fava M. An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorder. J Clin Psychiatry. 2005 Aug; 66(8):1038-42.
    View in: PubMed
  332. Petersen T, Papakostas GI, Posternak MA, Kant A, Guyker WM, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol. 2005 Aug; 25(4):336-41.
    View in: PubMed
  333. Papakostas GI, Petersen TJ, Green C, Iosifescu DV, Yeung AS, Nierenberg AA, Fava M, Posternak MA. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatry. 2005 Jul-Sep; 17(3):161-5.
    View in: PubMed
  334. Farabaugh A, Fava M, Mischoulon D, Sklarsky K, Petersen T, Alpert J. Relationships between major depressive disorder and comorbid anxiety and personality disorders. Compr Psychiatry. 2005 Jul-Aug; 46(4):266-71.
    View in: PubMed
  335. Rush AJ, Zimmerman M, Wisniewski SR, Fava M, Hollon SD, Warden D, Biggs MM, Shores-Wilson K, Shelton RC, Luther JF, Thomas B, Trivedi MH. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord. 2005 Jul; 87(1):43-55.
    View in: PubMed
  336. Papakostas GI, Petersen TJ, Burns AM, Fava M. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J Psychiatr Res. 2006 Jun; 40(4):370-3.
    View in: PubMed
  337. Papakostas GI, Petersen T, Lebowitz BD, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Alpert JE, Rosenbaum JF, Fava M. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005 Dec; 8(4):523-8.
    View in: PubMed
  338. Cassano P, Lattanzi L, Fava M, Navari S, Battistini G, Abelli M, Cassano GB. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry. 2005 May; 50(6):357-60.
    View in: PubMed
  339. Farabaugh A, Mischoulon D, Fava M, Wu SL, Mascarini A, Tossani E, Alpert JE. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol. 2005 Mar; 20(2):87-91.
    View in: PubMed
  340. Tossani E, Cassano P, Fava M. Depression and renal disease. Semin Dial. 2005 Mar-Apr; 18(2):73-81.
    View in: PubMed
  341. Perlis RH, Fraguas R, Fava M, Trivedi MH, Luther JF, Wisniewski SR, Rush AJ. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J Clin Psychiatry. 2005 Feb; 66(2):159-66; quiz 147, 273-4.
    View in: PubMed
  342. Cassano P, Soares CN, Cusin C, Mascarini A, Cohen LS, Fava M. Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine. Psychother Psychosom. 2005; 74(6):362-5.
    View in: PubMed
  343. Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005; 7(3):106-13.
    View in: PubMed
  344. Ongur D, Farabaugh A, Iosifescu DV, Perlis R, Fava M. Tridimensional personality questionnaire factors in major depressive disorder: relationship to anxiety disorder comorbidity and age of onset. Psychother Psychosom. 2005; 74(3):173-8.
    View in: PubMed
  345. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry. 2005 Jan; 66(1):85-93.
    View in: PubMed
  346. Yang H, Cusin C, Fava M. Is there a placebo problem in antidepressant trials? Curr Top Med Chem. 2005; 5(11):1077-86.
    View in: PubMed
  347. Yeung A, Kung WW, Murakami JL, Mischoulon D, Alpert JE, Nierenberg AA, Fava M. Outcomes of recognizing depressed Chinese American patients in primary care. Int J Psychiatry Med. 2005; 35(3):213-24.
    View in: PubMed
  348. Zisook S, Rush AJ, Albala A, Alpert J, Balasubramani GK, Fava M, Husain M, Sackeim H, Trivedi M, Wisniewski S. Factors that differentiate early vs. later onset of major depression disorder. Psychiatry Res. 2004 Dec 15; 129(2):127-40.
    View in: PubMed
  349. Farabaugh AH, Mischoulon D, Fava M, Green C, Guyker W, Alpert J. The potential relationship between levels of perceived stress and subtypes of major depressive disorder (MDD). Acta Psychiatr Scand. 2004 Dec; 110(6):465-70.
    View in: PubMed
  350. Alpert JE, Papakostas G, Mischoulon D, Worthington JJ, Petersen T, Mahal Y, Burns A, Bottiglieri T, Nierenberg AA, Fava M. S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine. J Clin Psychopharmacol. 2004 Dec; 24(6):661-4.
    View in: PubMed
  351. Nierenberg AA, Trivedi MH, Ritz L, Burroughs D, Greist J, Sackeim H, Kornstein S, Schwartz T, Stegman D, Fava M, Wisniewski SR. Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines. J Psychiatr Res. 2004 Nov-Dec; 38(6):583-9.
    View in: PubMed
  352. Yates WR, Mitchell J, Rush AJ, Trivedi MH, Wisniewski SR, Warden D, Hauger RB, Fava M, Gaynes BN, Husain MM, Bryan C. Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. Gen Hosp Psychiatry. 2004 Nov-Dec; 26(6):421-9.
    View in: PubMed
  353. Farabaugh A, Mischoulon D, Fava M, Guyker W, Alpert J. The overlap between personality disorders and major depressive disorder (MDD). Ann Clin Psychiatry. 2004 Oct-Dec; 16(4):217-24.
    View in: PubMed
  354. Papakostas GI, Petersen T, Denninger JW, Tossani E, Pava JA, Alpert JE, Nierenberg AA, Fava M. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol. 2004 Oct; 24(5):507-11.
    View in: PubMed
  355. Fava M, Alpert JE, Carmin CN, Wisniewski SR, Trivedi MH, Biggs MM, Shores-Wilson K, Morgan D, Schwartz T, Balasubramani GK, Rush AJ. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol Med. 2004 Oct; 34(7):1299-308.
    View in: PubMed
  356. Murck H, Fava M, Alpert J, Nierenberg AA, Mischoulon D, Otto MW, Zajecka J, Mannel M, Rosenbaum JF. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int J Neuropsychopharmacol. 2005 Jun; 8(2):215-21.
    View in: PubMed
  357. Papakostas GI, Petersen T, Iosifescu DV, Burns AM, Nierenberg AA, Alpert JE, Rosenbaum JF, Fava M. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol. 2005 Mar; 8(1):59-63.
    View in: PubMed
  358. Iosifescu DV, Nierenberg AA, Alpert JE, Papakostas GI, Perlis RH, Sonawalla S, Fava M. Comorbid medical illness and relapse of major depressive disorder in the continuation phase of treatment. Psychosomatics. 2004 Sep-Oct; 45(5):419-25.
    View in: PubMed
  359. Dougherty DD, Rauch SL, Deckersbach T, Marci C, Loh R, Shin LM, Alpert NM, Fischman AJ, Fava M. Ventromedial prefrontal cortex and amygdala dysfunction during an anger induction positron emission tomography study in patients with major depressive disorder with anger attacks. Arch Gen Psychiatry. 2004 Aug; 61(8):795-804.
    View in: PubMed
  360. Papakostas GI, Petersen T, Mischoulon D, Green CH, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004 Aug; 65(8):1096-8.
    View in: PubMed
  361. Papakostas GI, Iosifescu DV, Petersen T, Hamill SK, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. J Clin Psychopharmacol. 2004 Aug; 24(4):467-9.
    View in: PubMed
  362. Papakostas GI, Petersen T, Mischoulon D, Ryan JL, Nierenberg AA, Bottiglieri T, Rosenbaum JF, Alpert JE, Fava M. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004 Aug; 65(8):1090-5.
    View in: PubMed
  363. Alpert JE, Franznick DA, Hollander SB, Fava M. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. J Clin Psychiatry. 2004 Aug; 65(8):1069-75.
    View in: PubMed
  364. Yeung A, Kung WW, Chung H, Rubenstein G, Roffi P, Mischoulon D, Fava M. Integrating psychiatry and primary care improves acceptability to mental health services among Chinese Americans. Gen Hosp Psychiatry. 2004 Jul-Aug; 26(4):256-60.
    View in: PubMed
  365. Petersen T, Papakostas GI, Mahal Y, Guyker WM, Beaumont EC, Alpert JE, Fava M, Nierenberg AA. Psychosocial functioning in patients with treatment resistant depression. Eur Psychiatry. 2004 Jun; 19(4):196-201.
    View in: PubMed
  366. Iosifescu DV, Bankier B, Fava M. Impact of medical comorbid disease on antidepressant treatment of major depressive disorder. Curr Psychiatry Rep. 2004 Jun; 6(3):193-201.
    View in: PubMed
  367. Papakostas GI, Petersen T, Hughes ME, Nierenberg AA, Alpert JE, Fava M. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Psychiatry Res. 2004 May 30; 126(3):287-90.
    View in: PubMed
  368. Wisniewski SR, Stegman D, Trivedi M, Husain MM, Eng H, Shores-Wilson K, Luther J, Biggs MM, Burroughs D, Ritz AL, Fava M, Quitkin F, Rush AJ. Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D). J Psychiatr Res. 2004 May-Jun; 38(3):241-8.
    View in: PubMed
  369. Perlis RH, Iosifescu DV, Alpert J, Nierenberg AA, Rosenbaum JF, Fava M. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. Psychosomatics. 2004 May-Jun; 45(3):224-9.
    View in: PubMed
  370. Cassano P, Soares CN, Cohen LS, Lyster AK, Fava M. Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine. Arch Womens Ment Health. 2004 Jul; 7(3):167-71.
    View in: PubMed
  371. Perlis RH, Smoller JW, Fava M, Rosenbaum JF, Nierenberg AA, Sachs GS. The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. J Affect Disord. 2004 Apr; 79(1-3):291-5.
    View in: PubMed
  372. Papakostas GI, Petersen TJ, Iosifescu DV, Summergrad P, Sklarsky KG, Alpert JE, Nierenberg AA, Fava M. Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. J Clin Psychiatry. 2004 Apr; 65(4):543-6.
    View in: PubMed
  373. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry. 2004 Apr; 65(4):521-30.
    View in: PubMed
  374. Petersen T, Harley R, Papakostas GI, Montoya HD, Fava M, Alpert JE. Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine. Psychol Med. 2004 Apr; 34(3):555-61.
    View in: PubMed
  375. Yeung A, Chang D, Gresham RL, Nierenberg AA, Fava M. Illness beliefs of depressed Chinese American patients in primary care. J Nerv Ment Dis. 2004 Apr; 192(4):324-7.
    View in: PubMed
  376. Papakostas GI, Ongür D, Iosifescu DV, Mischoulon D, Fava M. Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. Eur Neuropsychopharmacol. 2004 Mar; 14(2):135-42.
    View in: PubMed
  377. Joliat MJ, Schmidt ME, Fava M, Zhang S, Michelson D, Trapp NJ, Miner CM. Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. J Clin Psychiatry. 2004 Mar; 65(3):373-8.
    View in: PubMed
  378. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004 Feb; 25(1):119-42.
    View in: PubMed
  379. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004 Feb; 65(2):217-21.
    View in: PubMed
  380. Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004 Jan-Feb; 26(1):13-7.
    View in: PubMed
  381. Mischoulon D, Opitz G, Kelly K, Fava M, Rosenbaum JF. A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment. Depress Anxiety. 2004; 19(1):43-50.
    View in: PubMed
  382. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry. 2004; 65 Suppl 16:27-32.
    View in: PubMed
  383. Cassano P, Fava M. Tolerability issues during long-term treatment with antidepressants. Ann Clin Psychiatry. 2004 Jan-Mar; 16(1):15-25.
    View in: PubMed
  384. Yeung A, Chan R, Mischoulon D, Sonawalla S, Wong E, Nierenberg AA, Fava M. Prevalence of major depressive disorder among Chinese-Americans in primary care. Gen Hosp Psychiatry. 2004 Jan-Feb; 26(1):24-30.
    View in: PubMed
  385. Perlis RH, Alpert J, Nierenberg AA, Mischoulon D, Yeung A, Rosenbaum JF, Fava M. Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Acta Psychiatr Scand. 2003 Dec; 108(6):432-8.
    View in: PubMed
  386. Papakostas GI, Alpert JE, Fava M. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr Psychiatry Rep. 2003 Dec; 5(6):460-6.
    View in: PubMed
  387. Iosifescu DV, Nierenberg AA, Alpert JE, Smith M, Bitran S, Dording C, Fava M. The impact of medical comorbidity on acute treatment in major depressive disorder. Am J Psychiatry. 2003 Dec; 160(12):2122-7.
    View in: PubMed
  388. Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM, Rosenbaum JF, Fava M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry. 2003 Nov 1; 54(9):879-83.
    View in: PubMed
  389. Papakostas GI, Petersen TJ, Farabaugh AH, Murakami JL, Pava JA, Alpert JE, Fava M, Nierenberg AA. Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. J Clin Psychiatry. 2003 Nov; 64(11):1357-61.
    View in: PubMed
  390. Papakostas GI, Petersen T, Denninger JW, Montoya HD, Nierenberg AA, Alpert JE, Fava M. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder. Ann Clin Psychiatry. 2003 Sep-Dec; 15(3-4):187-92.
    View in: PubMed
  391. Papakostas GI, Petersen T, Worthington JJ, Roffi PA, Alpert JE, Fava M, Nierenberg AA. A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. Int Clin Psychopharmacol. 2003 Sep; 18(5):293-6.
    View in: PubMed
  392. Fava M, McGrath PJ, Sheu WP. Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J Clin Psychopharmacol. 2003 Aug; 23(4):365-9.
    View in: PubMed
  393. Sachs GS, Thase ME, Otto MW, Bauer M, Miklowitz D, Wisniewski SR, Lavori P, Lebowitz B, Rudorfer M, Frank E, Nierenberg AA, Fava M, Bowden C, Ketter T, Marangell L, Calabrese J, Kupfer D, Rosenbaum JF. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003 Jun 1; 53(11):1028-42.
    View in: PubMed
  394. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, Kupfer DJ. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003 Jun; 26(2):457-94, x.
    View in: PubMed
  395. Papakostas GI, Petersen T, Iosifescu DV, Roffi PA, Alpert JE, Rosenbaum JF, Fava M, Nierenberg AA. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):183-8.
    View in: PubMed
  396. Papakostas GI, Petersen T, Mischoulon D, Hughes ME, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. Serum cholesterol and serotonergic function in major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):137-45.
    View in: PubMed
  397. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003 May-Jun; 72(3):115-27.
    View in: PubMed
  398. Papakostas GI, Petersen T, Denninger J, Sonawalla SB, Mahal Y, Alpert JE, Nierenberg AA, Fava M. Somatic symptoms in treatment-resistant depression. Psychiatry Res. 2003 May 1; 118(1):39-45.
    View in: PubMed
  399. Simon NM, Smoller JW, Fava M, Sachs G, Racette SR, Perlis R, Sonawalla S, Rosenbaum JF. Comparing anxiety disorders and anxiety-related traits in bipolar disorder and unipolar depression. J Psychiatr Res. 2003 May-Jun; 37(3):187-92.
    View in: PubMed
  400. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003 Apr 15; 53(8):649-59.
    View in: PubMed
  401. Quitkin FM, Petkova E, McGrath PJ, Taylor B, Beasley C, Stewart J, Amsterdam J, Fava M, Rosenbaum J, Reimherr F, Fawcett J, Chen Y, Klein D. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry. 2003 Apr; 160(4):734-40.
    View in: PubMed
  402. Morris MS, Fava M, Jacques PF, Selhub J, Rosenberg IH. Depression and folate status in the US Population. Psychother Psychosom. 2003 Mar-Apr; 72(2):80-7.
    View in: PubMed
  403. Fava M, Papakostas GI, Petersen T, Mahal Y, Quitkin F, Stewart J, McGrath P. Switching to bupropion in fluoxetine-resistant major depressive disorder. Ann Clin Psychiatry. 2003 Mar; 15(1):17-22.
    View in: PubMed
  404. Alpert JE, Petersen T, Roffi PA, Papakostas GI, Freed R, Smith MM, Spector AR, Nierenberg AA, Rosenbaum JF, Fava M. Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks. Psychother Psychosom. 2003 Mar-Apr; 72(2):102-6.
    View in: PubMed
  405. Nierenberg AA, Papakostas GI, Petersen T, Montoya HD, Worthington JJ, Tedlow J, Alpert JE, Fava M. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol. 2003 Feb; 23(1):92-5.
    View in: PubMed
  406. Rush AJ, Trivedi M, Fava M. Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry. 2003 Feb; 160(2):237.
    View in: PubMed
  407. Fava M. Depression with physical symptoms: treating to remission. J Clin Psychiatry. 2003; 64 Suppl 7:24-8.
    View in: PubMed
  408. Petersen TJ, Alpert JE, Papakostas GI, Bernstein EM, Freed R, Smith MM, Fava M. Early-onset depression and the emotional and behavioral characteristics of offspring. Depress Anxiety. 2003; 18(2):104-8.
    View in: PubMed
  409. Nierenberg AA, Papakostas GI, Petersen T, Kelly KE, Iacoviello BM, Worthington JJ, Tedlow J, Alpert JE, Fava M. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003 Jan; 64(1):35-9.
    View in: PubMed
  410. Papakostas GI, Petersen T, Sonawalla SB, Merens W, Iosifescu DV, Alpert JE, Fava M, Nierenberg AA. Serum cholesterol in treatment-resistant depression. Neuropsychobiology. 2003; 47(3):146-51.
    View in: PubMed
  411. Fava M. The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry. 2003; 64 Suppl 13:26-9.
    View in: PubMed
  412. Fava M. Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. J Clin Psychiatry. 2003; 64 Suppl 14:30-4.
    View in: PubMed
  413. Papakostas GI, Petersen T, Mischoulon D, Hughes ME, Spector AR, Alpert JE, Fava M, Nierenberg AA. Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. Compr Psychiatry. 2003 Jan-Feb; 44(1):44-50.
    View in: PubMed
  414. Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003 Jan 1; 289(1):56-64.
    View in: PubMed
  415. Mischoulon D, Dougherty DD, Bottonari KA, Gresham RL, Sonawalla SB, Fischman AJ, Fava M. An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor binding. Psychiatry Res. 2002 Dec 30; 116(3):151-61.
    View in: PubMed
  416. Matthews JD, Bottonari KA, Polania LM, Mischoulon D, Dording CM, Irvin R, Fava M. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses. J Clin Psychiatry. 2002 Dec; 63(12):1164-70.
    View in: PubMed
  417. Sonawalla SB, Farabaugh AH, Leslie VM, Pava JA, Matthews JD, Fava M. Early drop-outs, late drop-outs and completers: differences in the continuation phase of a clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Dec; 26(7-8):1415-9.
    View in: PubMed
  418. Booij L, Van der Does W, Benkelfat C, Bremner JD, Cowen PJ, Fava M, Gillin C, Leyton M, Moore P, Smith KA, Van der Kloot WA. Predictors of mood response to acute tryptophan depletion. A reanalysis. Neuropsychopharmacology. 2002 Nov; 27(5):852-61.
    View in: PubMed
  419. Mischoulon D, Fava M. Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr. 2002 Nov; 76(5):1158S-61S.
    View in: PubMed
  420. Cassano P, Fava M. Depression and public health: an overview. J Psychosom Res. 2002 Oct; 53(4):849-57.
    View in: PubMed
  421. Perlis RH, Nierenberg AA, Alpert JE, Pava J, Matthews JD, Buchin J, Sickinger AH, Fava M. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. J Clin Psychopharmacol. 2002 Oct; 22(5):474-80.
    View in: PubMed
  422. Sonawalla SB, Farabaugh A, Johnson MW, Morray M, Delgado ML, Pingol MG, Rosenbaum JF, Fava M. Fluoxetine treatment of depressed patients with comorbid anxiety disorders. J Psychopharmacol. 2002 Sep; 16(3):215-9.
    View in: PubMed
  423. Petersen T, Hughes M, Papakostas GI, Kant A, Fava M, Rosenbaum JF, Nierenberg AA. Treatment-resistant depression and Axis II comorbidity. Psychother Psychosom. 2002 Sep-Oct; 71(5):269-74.
    View in: PubMed
  424. Nurnberg HG, Seidman SN, Gelenberg AJ, Fava M, Rosen R, Shabsigh R. Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression. Urology. 2002 Sep; 60(2 Suppl 2):58-66.
    View in: PubMed
  425. Dording CM, Mischoulon D, Petersen TJ, Kornbluh R, Gordon J, Nierenberg AA, Rosenbaum JE, Fava M. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry. 2002 Sep; 14(3):143-7.
    View in: PubMed
  426. Tedlow J, Smith M, Neault N, Polania L, Alpert J, Nierenberg A, Fava M. Melancholia and axis II comorbidity. Compr Psychiatry. 2002 Sep-Oct; 43(5):331-5.
    View in: PubMed
  427. Fava M, Farabaugh AH, Sickinger AH, Wright E, Alpert JE, Sonawalla S, Nierenberg AA, Worthington JJ. Personality disorders and depression. Psychol Med. 2002 Aug; 32(6):1049-57.
    View in: PubMed
  428. Fava M, Alpert J, Nierenberg A, Lagomasino I, Sonawalla S, Tedlow J, Worthington J, Baer L, Rosenbaum JF. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002 Aug; 22(4):379-87.
    View in: PubMed
  429. Fava M, Schmidt ME, Zhang S, Gonzales J, Raute NJ, Judge R. Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment. Psychother Psychosom. 2002 Jul-Aug; 71(4):195-9.
    View in: PubMed
  430. Sonawalla SB, Papakostas GI, Petersen TJ, Yeung AS, Smith MM, Sickinger AH, Gordon J, Israel JA, Tedlow JR, Lamon-Fava S, Fava M. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics. 2002 Jul-Aug; 43(4):310-6.
    View in: PubMed
  431. Schmidt ME, Fava M, Zhang S, Gonzales J, Raute NJ, Judge R. Treatment approaches to major depressive disorder relapse. Part 1: dose increase. Psychother Psychosom. 2002 Jul-Aug; 71(4):190-4.
    View in: PubMed
  432. Nierenberg AA, Phillips KA, Petersen TJ, Kelly KE, Alpert JE, Worthington JJ, Tedlow JR, Rosenbaum JF, Fava M. Body dysmorphic disorder in outpatients with major depression. J Affect Disord. 2002 May; 69(1-3):141-8.
    View in: PubMed
  433. Farabaugh A, Mischoulon D, Yeung A, Alpert J, Matthews J, Pava J, Fava M. Predictors of stable personality disorder diagnoses in outpatients with remitted depression. J Nerv Ment Dis. 2002 Apr; 190(4):248-56.
    View in: PubMed
  434. Sonawalla SB, Farabaugh AH, Leslie VM, Pava JA, Matthews JD, Fava M. Early drop-outs, late drop-outs and completers: differences in the continuation phase of a clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr; 26(3):415-9.
    View in: PubMed
  435. Fava M. Somatic symptoms, depression, and antidepressant treatment. J Clin Psychiatry. 2002 Apr; 63(4):305-7.
    View in: PubMed
  436. Fava M, Hoog SL, Judge RA, Kopp JB, Nilsson ME, Gonzales JS. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol. 2002 Apr; 22(2):137-47.
    View in: PubMed
  437. Yeung A, Neault N, Sonawalla S, Howarth S, Fava M, Nierenberg AA. Screening for major depression in Asian-Americans: a comparison of the Beck and the Chinese Depression Inventory. Acta Psychiatr Scand. 2002 Apr; 105(4):252-7.
    View in: PubMed
  438. Perlis RH, Fava M, Nierenberg AA, Pollack MH, Falk WE, Kienke AS, Rosenbaum JF. Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry. 2002 Mar-Apr; 10(2):109-14.
    View in: PubMed
  439. Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA, Fava M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression. Ann Clin Psychiatry. 2002 Mar; 14(1):33-8.
    View in: PubMed
  440. Yeung A, Howarth S, Chan R, Sonawalla S, Nierenberg AA, Fava M. Use of the Chinese version of the Beck Depression Inventory for screening depression in primary care. J Nerv Ment Dis. 2002 Feb; 190(2):94-9.
    View in: PubMed
  441. Petersen T, Papakostas GI, Bottonari K, Iacoviello B, Alpert JE, Fava M, Nierenberg AA. NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients. Psychiatry Res. 2002 Jan 31; 109(1):9-16.
    View in: PubMed
  442. Fava M, Rankin M. Sexual functioning and SSRIs. J Clin Psychiatry. 2002; 63 Suppl 5:13-6; discussion 23-5.
    View in: PubMed
  443. Petersen T, Dording C, Neault NB, Kornbluh R, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan; 26(1):177-87.
    View in: PubMed
  444. Renshaw PF, Parow AM, Hirashima F, Ke Y, Moore CM, Frederick Bde B, Fava M, Hennen J, Cohen BM. Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. Am J Psychiatry. 2001 Dec; 158(12):2048-55.
    View in: PubMed
  445. Petersen T, Bottonari K, Alpert JE, Fava M, Nierenberg AA. Use of the five-factory inventory in characterizing patients with major depressive disorder. Compr Psychiatry. 2001 Nov-Dec; 42(6):488-93.
    View in: PubMed
  446. Blais MA, Otto MW, Zucker BG, McNally RJ, Schmidt NB, Fava M, Pollack MH. The anxiety sensitivity index: item analysis and suggestions for refinement. J Pers Assess. 2001 Oct; 77(2):272-94.
    View in: PubMed
  447. Petersen T, Gordon JA, Kant A, Fava M, Rosenbaum JF, Nierenberg AA. Treatment resistant depression and axis I co-morbidity. Psychol Med. 2001 Oct; 31(7):1223-9.
    View in: PubMed
  448. Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry. 2001 Jun; 62(6):413-20.
    View in: PubMed
  449. Spillmann MK, Van der Does AJ, Rankin MA, Vuolo RD, Alpert JE, Nierenberg AA, Rosenbaum JF, Hayden D, Schoenfeld D, Fava M. Tryptophan depletion in SSRI-recovered depressed outpatients. Psychopharmacology (Berl). 2001 May; 155(2):123-7.
    View in: PubMed
  450. Mischoulon D, McColl-Vuolo R, Howarth S, Lagomasino IT, Alpert JE, Nierenberg AA, Fava M. Management of major depression in the primary care setting. Psychother Psychosom. 2001 Mar-Apr; 70(2):103-7.
    View in: PubMed
  451. Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs. 2001; 15(10):765-76.
    View in: PubMed
  452. Iosifescu DV, Howarth S, Alpert JE, Nierenberg AA, Worthington JJ, Fava M. T3 blood levels and treatment outcome in depression. Int J Psychiatry Med. 2001; 31(4):367-73.
    View in: PubMed
  453. Fava M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001; 62 Suppl 18:4-11.
    View in: PubMed
  454. Kornbluh R, Papakostas GI, Petersen T, Neault NB, Nierenberg AA, Rosenbaum JF, Fava M. A survey of prescribing preferences in the treatment of refractory depression: recent trends. Psychopharmacol Bull. 2001; 35(3):150-6.
    View in: PubMed
  455. Mischoulon D, Fava M. Docosahexanoic acid and omega-3 fatty acids in depression. Psychiatr Clin North Am. 2000 Dec; 23(4):785-94.
    View in: PubMed
  456. Fava M, Kendler KS. Major depressive disorder. Neuron. 2000 Nov; 28(2):335-41.
    View in: PubMed
  457. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry. 2000 Nov; 61(11):863-7.
    View in: PubMed
  458. Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS, Rosenbaum JF, Fava M. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry. 2000 Sep; 12(3):137-40.
    View in: PubMed
  459. Mischoulon D, Burger JK, Spillmann MK, Worthington JJ, Fava M, Alpert JE. Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression. J Psychosom Res. 2000 Sep; 49(3):183-7.
    View in: PubMed
  460. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000 Sep; 157(9):1423-8.
    View in: PubMed
  461. Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord. 2000 Aug; 59(2):119-26.
    View in: PubMed
  462. Alpert JE, Mischoulon D, Nierenberg AA, Fava M. Nutrition and depression: focus on folate. Nutrition. 2000 Jul-Aug; 16(7-8):544-6.
    View in: PubMed
  463. Vakili K, Pillay SS, Lafer B, Fava M, Renshaw PF, Bonello-Cintron CM, Yurgelun-Todd DA. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study. Biol Psychiatry. 2000 Jun 15; 47(12):1087-90.
    View in: PubMed
  464. Fredman SJ, Fava M, Kienke AS, White CN, Nierenberg AA, Rosenbaum JF. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry. 2000 Jun; 61(6):403-8.
    View in: PubMed
  465. Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry. 2000 Jun; 45(5):476-81.
    View in: PubMed
  466. Fava M, Vuolo RD, Wright EC, Nierenberg AA, Alpert JE, Rosenbaum JF. Fenfluramine challenge in unipolar depression with and without anger attacks. Psychiatry Res. 2000 Apr 24; 94(1):9-18.
    View in: PubMed
  467. Matthews JD, Fava M. Risk of suicidality in depression with serotonergic antidepressants. Ann Clin Psychiatry. 2000 Mar; 12(1):43-50.
    View in: PubMed
  468. Fava M, Rankin MA, Wright EC, Alpert JE, Nierenberg AA, Pava J, Rosenbaum JF. Anxiety disorders in major depression. Compr Psychiatry. 2000 Mar-Apr; 41(2):97-102.
    View in: PubMed
  469. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000; 61 Suppl 11:37-41.
    View in: PubMed
  470. Fava M. Management of nonresponse and intolerance: switching strategies. J Clin Psychiatry. 2000; 61 Suppl 2:10-2.
    View in: PubMed
  471. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry. 2000; 61 Suppl 1:26-32.
    View in: PubMed
  472. Baer L, Jacobs DG, Meszler-Reizes J, Blais M, Fava M, Kessler R, Magruder K, Murphy J, Kopans B, Cukor P, Leahy L, O'Laughlen J. Development of a brief screening instrument: the HANDS. Psychother Psychosom. 2000; 69(1):35-41.
    View in: PubMed
  473. Newman JR, Ewing SE, McColl RD, Borus JS, Nierenberg AA, Pava J, Fava M. Tridimensional personality questionnaire and treatment response in major depressive disorder: a negative study. J Affect Disord. 2000 Jan-Mar; 57(1-3):241-7.
    View in: PubMed
  474. Winkelman JW, Herzog DB, Fava M. The prevalence of sleep-related eating disorder in psychiatric and non-psychiatric populations. Psychol Med. 1999 Nov; 29(6):1461-6.
    View in: PubMed
  475. Sonawalla SB, Renshaw PF, Moore CM, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am J Psychiatry. 1999 Oct; 156(10):1638-40.
    View in: PubMed
  476. Sonawalla SB, Spillmann MK, Kolsky AR, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J Clin Psychiatry. 1999 Sep; 60(9):580-3.
    View in: PubMed
  477. Cannon B, Mulroy R, Otto MW, Rosenbaum JF, Fava M, Nierenberg AA. Dysfunctional attitudes and poor problem solving skills predict hopelessness in major depression. J Affect Disord. 1999 Sep; 55(1):45-9.
    View in: PubMed
  478. Fava M, Rosenbaum JF, Kolsky AR, Alpert JE, Nierenberg AA, Spillmann M, Moore C, Renshaw P, Bottiglieri T, Moroz G, Magni G. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol. 1999 Aug; 19(4):329-35.
    View in: PubMed
  479. Alpert JE, Fava M, Uebelacker LA, Nierenberg AA, Pava JA, Worthington JJ, Rosenbaum JF. Patterns of axis I comorbidity in early-onset versus late-onset major depressive disorder. Biol Psychiatry. 1999 Jul 15; 46(2):202-11.
    View in: PubMed
  480. Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ, Rosenbaum JF, Fava M. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999 Apr; 60(4):221-5.
    View in: PubMed
  481. Mischoulon D, Fava M, Rosenbaum JF. Strategies for augmentation of SSRI treatment: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry. 1999 Mar-Apr; 6(6):322-6.
    View in: PubMed
  482. Tedlow J, Leslie V, Keefe BR, Alpert J, Nierenberg AA, Rosenbaum JF, Fava M. Axis I and Axis II disorder comorbidity in unipolar depression with anger attacks. J Affect Disord. 1999 Jan-Mar; 52(1-3):217-23.
    View in: PubMed
  483. Fava M, Rosenbaum JF. Anger attacks in patients with depression. J Clin Psychiatry. 1999; 60 Suppl 15:21-4.
    View in: PubMed
  484. Pillay SS, Renshaw PF, Bonello CM, Lafer BC, Fava M, Yurgelun-Todd D. A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. Psychiatry Res. 1998 Dec 14; 84(2-3):61-74.
    View in: PubMed
  485. Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry. 1998 Dec; 10(4):145-50.
    View in: PubMed
  486. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998 Jul 15; 44(2):77-87.
    View in: PubMed
  487. Tedlow J, Fava M, Uebelacker L, Nierenberg AA, Alpert JE, Rosenbaum J. Outcome definitions and predictors in depression. Psychother Psychosom. 1998 Jul-Oct; 67(4-5):266-70.
    View in: PubMed
  488. Otto MW, Demopulos CM, McLean NE, Pollack MH, Fava M. Additional findings on the association between anxiety sensitivity and hypochondriacal concerns: examination of patients with major depression. J Anxiety Disord. 1998 May-Jun; 12(3):225-32.
    View in: PubMed
  489. Fava M, Rankin MA, Alpert JE, Nierenberg AA, Worthington JJ. An open trial of oral sildenafilin antidepressant-induced sexual dysfunction. Psychother Psychosom. 1998; 67(6):328-31.
    View in: PubMed
  490. Fava M, Rosenbaum JF. Anger attacks in depression. Depress Anxiety. 1998; 8 Suppl 1:59-63.
    View in: PubMed
  491. Nierenberg AA, Alpert JE, Pava J, Rosenbaum JF, Fava M. Course and treatment of atypical depression. J Clin Psychiatry. 1998; 59 Suppl 18:5-9.
    View in: PubMed
  492. Fava M. Depression with anger attacks. J Clin Psychiatry. 1998; 59 Suppl 18:18-22.
    View in: PubMed
  493. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997 Dec; 154(12):1760-2.
    View in: PubMed
  494. Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Pava JA, Rosenbaum JF. Major depressive subtypes and treatment response. Biol Psychiatry. 1997 Oct 1; 42(7):568-76.
    View in: PubMed
  495. Pillay SS, Yurgelun-Todd DA, Bonello CM, Lafer B, Fava M, Renshaw PF. A quantitative magnetic resonance imaging study of cerebral and cerebellar gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity. Biol Psychiatry. 1997 Jul 15; 42(2):79-84.
    View in: PubMed
  496. Fava M. [Anger outbursts in unipolar depressive disorders]. Encephale. 1997 Jun; 23 Spec No 3:39-42.
    View in: PubMed
  497. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am. 1997 Jun; 20(2):427-51.
    View in: PubMed
  498. Alpert JE, Fava M. Nutrition and depression: the role of folate. Nutr Rev. 1997 May; 55(5):145-9.
    View in: PubMed
  499. Alpert JE, Uebelacker LA, McLean NE, Nierenberg AA, Pava JA, Worthington JJ, Tedlow JR, Rosenbaum JF, Fava M. Social phobia, avoidant personality disorder and atypical depression: co-occurrence and clinical implications. Psychol Med. 1997 May; 27(3):627-33.
    View in: PubMed
  500. Renshaw PF, Lafer B, Babb SM, Fava M, Stoll AL, Christensen JD, Moore CM, Yurgelun-Todd DA, Bonello CM, Pillay SS, Rothschild AJ, Nierenberg AA, Rosenbaum JF, Cohen BM. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 1997 Apr 15; 41(8):837-43.
    View in: PubMed
  501. Fava M, Abraham M, Clancy-Colecchi K, Pava JA, Matthews J, Rosenbaum JF. Eating disorder symptomatology in major depression. J Nerv Ment Dis. 1997 Mar; 185(3):140-4.
    View in: PubMed
  502. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry. 1997 Mar; 154(3):426-8.
    View in: PubMed
  503. Fava M, Nierenberg AA, Quitkin FM, Zisook S, Pearlstein T, Stone A, Rosenbaum JF. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacol Bull. 1997; 33(1):101-3.
    View in: PubMed
  504. Moore CM, Christensen JD, Lafer B, Fava M, Renshaw PF. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry. 1997 Jan; 154(1):116-8.
    View in: PubMed
  505. Spillmann M, Borus JS, Davidson KG, Worthington JJ, Tedlow JR, Fava M. Sociodemographic predictors of response to antidepressant treatment. Int J Psychiatry Med. 1997; 27(2):129-36.
    View in: PubMed
  506. Worthington J, Fava M, Agustin C, Alpert J, Nierenberg AA, Pava JA, Rosenbaum JF. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics. 1996 Nov-Dec; 37(6):518-22.
    View in: PubMed
  507. Fava M, Davidson K, Alpert JE, Nierenberg AA, Worthington J, O'Sullivan R, Rosenbaum JF. Hostility changes following antidepressant treatment: relationship to stress and negative thinking. J Psychiatr Res. 1996 Nov-Dec; 30(6):459-67.
    View in: PubMed
  508. Nierenberg AA, Pava JA, Clancy K, Rosenbaum JF, Fava M. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? Biol Psychiatry. 1996 Oct 15; 40(8):691-6.
    View in: PubMed
  509. Tedlow JR, Fava M, Uebelacker LA, Alpert JE, Nierenberg AA, Rosenbaum JF. Are study dropouts different from completers? Biol Psychiatry. 1996 Oct 1; 40(7):668-70.
    View in: PubMed
  510. Fava M. Traditional and alternative research designs and methods in clinical pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry. 1996 Oct; 35(10):1292-303.
    View in: PubMed
  511. Fava M, Alpert JE, Borus JS, Nierenberg AA, Pava JA, Rosenbaum JF. Patterns of personality disorder comorbidity in early-onset versus late-onset major depression. Am J Psychiatry. 1996 Oct; 153(10):1308-12.
    View in: PubMed
  512. Nierenberg AA, Ghaemi SN, Clancy-Colecchi K, Rosenbaum JF, Fava M. Cynicism, hostility, and suicidal ideation in depressed outpatients. J Nerv Ment Dis. 1996 Oct; 184(10):607-10.
    View in: PubMed
  513. Demopulos C, Fava M, McLean NE, Alpert JE, Nierenberg AA, Rosenbaum JF. Hypochondriacal concerns in depressed outpatients. Psychosom Med. 1996 Jul-Aug; 58(4):314-20.
    View in: PubMed
  514. Gould RA, Ball S, Kaspi SP, Otto MW, Pollack MH, Shekhar A, Fava M. Prevalence and correlates of anger attacks: a two site study. J Affect Disord. 1996 Jun 20; 39(1):31-8.
    View in: PubMed
  515. Fava M, Abraham M, Alpert J, Nierenberg AA, Pava JA, Rosenbaum JF. Gender differences in Axis I comorbidity among depressed outpatients. J Affect Disord. 1996 Jun 5; 38(2-3):129-33.
    View in: PubMed
  516. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996 Jun; 19(2):179-200.
    View in: PubMed
  517. Alpert JE, Maddocks A, Nierenberg AA, O'Sullivan R, Pava JA, Worthington JJ, Biederman J, Rosenbaum JF, Fava M. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res. 1996 Jun 1; 62(3):213-9.
    View in: PubMed
  518. Fava M, Alpert J, Nierenberg AA, Ghaemi N, O'Sullivan R, Tedlow J, Worthington J, Rosenbaum JF. Fluoxetine treatment of anger attacks: a replication study. Ann Clin Psychiatry. 1996 Mar; 8(1):7-10.
    View in: PubMed
  519. Fava M, Abraham M, Pava J, Shuster J, Rosenbaum J. Cardiovascular risk factors in depression. The role of anxiety and anger. Psychosomatics. 1996 Jan-Feb; 37(1):31-7.
    View in: PubMed
  520. Lafer B, Nierenberg AA, Rosenbaum JF, Fava M. Outpatients with DSM-III-R versus DSM-IV melancholic depression. Compr Psychiatry. 1996 Jan-Feb; 37(1):37-9.
    View in: PubMed
  521. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995 Oct; 152(10):1500-3.
    View in: PubMed
  522. Nierenberg AA, Grossbard SJ, Fava M, Rosenbaum JF. Social adjustment does not predict depressive relapse during continuation fluoxetine therapy. J Affect Disord. 1995 May 17; 34(2):73-7.
    View in: PubMed
  523. Fava M, Labbate LA, Abraham ME, Rosenbaum JF. Hypothyroidism and hyperthyroidism in major depression revisited. J Clin Psychiatry. 1995 May; 56(5):186-92.
    View in: PubMed
  524. Fava M, Giannelli A, Rapisarda V, Patralia A, Guaraldi GP. Rapidity of onset of the antidepressant effect of parenteral S-adenosyl-L-methionine. Psychiatry Res. 1995 Apr 28; 56(3):295-7.
    View in: PubMed
  525. Fava M, Rappe SM, West J, Herzog DB. Anger attacks in eating disorders. Psychiatry Res. 1995 Apr 28; 56(3):205-12.
    View in: PubMed
  526. Golomb M, Fava M, Abraham M, Rosenbaum JF. Gender differences in personality disorders. Am J Psychiatry. 1995 Apr; 152(4):579-82.
    View in: PubMed
  527. Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry. 1995 Feb; 56(2):52-5.
    View in: PubMed
  528. Golomb M, Fava M, Abraham M, Rosenbaum JF. The relationship between age and personality disorders in depressed outpatients. J Nerv Ment Dis. 1995 Jan; 183(1):43-4.
    View in: PubMed
  529. Worthington J, Fava M, Davidson K, Alpert J, Nierenberg AA, Rosenbaum JF. Patterns of improvement in depressive symptoms with fluoxetine treatment. Psychopharmacol Bull. 1995; 31(2):223-6.
    View in: PubMed
  530. Fava M, Nolan S, Kradin R, Rosenbaum J. Gender differences in hostility among depressed and medical outpatients. J Nerv Ment Dis. 1995 Jan; 183(1):10-4.
    View in: PubMed
  531. Alpert JE, Uebelacker LA, McLean NE, Abraham M, Rosenbaum JF, Fava M. The Mini-Mental State Examination among adult outpatients with major depressive disorder. Psychother Psychosom. 1995; 63(3-4):207-11.
    View in: PubMed
  532. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994 Sep; 151(9):1372-4.
    View in: PubMed
  533. Alpert JE, Maddocks A, Rosenbaum JF, Fava M. Childhood psychopathology retrospectively assessed among adults with early onset major depression. J Affect Disord. 1994 Jul; 31(3):165-71.
    View in: PubMed
  534. Fava M, Bouffides E, Pava JA, McCarthy MK, Steingard RJ, Rosenbaum JF. Personality disorder comorbidity with major depression and response to fluoxetine treatment. Psychother Psychosom. 1994; 62(3-4):160-7.
    View in: PubMed
  535. Fava M, Bless E, Otto MW, Pava JA, Rosenbaum JF. Dysfunctional attitudes in major depression. Changes with pharmacotherapy. J Nerv Ment Dis. 1994 Jan; 182(1):45-9.
    View in: PubMed
  536. Otto MW, Bruder GE, Fava M, Delis DC, Quitkin FM, Rosenbaum JF. Norms for depressed patients for the California verbal learning test: associations with depression severity and self-report of cognitive difficulties. Arch Clin Neuropsychol. 1994 Jan; 9(1):81-8.
    View in: PubMed
  537. Pava JA, Fava M, Levenson JA. Integrating cognitive therapy and pharmacotherapy in the treatment and prophylaxis of depression: a novel approach. Psychother Psychosom. 1994; 61(3-4):211-9.
    View in: PubMed
  538. Lafer B, Fava M, Hammerness P, Rosenbaum JF. The influence of DST and TRH test administration on depression assessments: a controlled study. Biol Psychiatry. 1993 Nov 1; 34(9):650-3.
    View in: PubMed
  539. Fava M, Rosenbaum JF. Psychopharmacology of pathologic aggression. Harv Rev Psychiatry. 1993 Nov-Dec; 1(4):244-6.
    View in: PubMed
  540. Callahan AM, Fava M, Rosenbaum JF. Drug interactions in psychopharmacology. Psychiatr Clin North Am. 1993 Sep; 16(3):647-71.
    View in: PubMed
  541. Fava M, Rosenbaum JF, Pava JA, McCarthy MK, Steingard RJ, Bouffides E. Anger attacks in unipolar depression, Part 1: Clinical correlates and response to fluoxetine treatment. Am J Psychiatry. 1993 Aug; 150(8):1158-63.
    View in: PubMed
  542. Rosenbaum JF, Fava M, Pava JA, McCarthy MK, Steingard RJ, Bouffides E. Anger attacks in unipolar depression, Part 2: Neuroendocrine correlates and changes following fluoxetine treatment. Am J Psychiatry. 1993 Aug; 150(8):1164-8.
    View in: PubMed
  543. Fava M, Anderson K, Rosenbaum JF. Are thymoleptic-responsive "anger attacks" a discrete clinical syndrome? Psychosomatics. 1993 Jul-Aug; 34(4):350-5.
    View in: PubMed
  544. Littman AB, Fava M, Halperin P, Lamon-Fava S, Drews FR, Oleshansky MA, Bielenda CC, MacLaughlin RA. Physiologic benefits of a stress reduction program for healthy middle-aged Army officers. J Psychosom Res. 1993 May; 37(4):345-54.
    View in: PubMed
  545. Greenes D, Fava M, Cioffi J, Herzog DB. The relationship of depression to dissociation in patients with bulimia nervosa. J Psychiatr Res. 1993 Apr-Jun; 27(2):133-7.
    View in: PubMed
  546. Littman AB, Fava M, McKool K, Lamon-Fava S, Pegg E. Buspirone therapy for Type A behavior, hostility, and perceived stress in cardiac patients. Psychother Psychosom. 1993; 59(2):107-10.
    View in: PubMed
  547. Fava M, Littman A, Lamon-Fava S, Milani R, Shera D, MacLaughlin R, Cassem E, Leaf A, Marchiò B, Bolognesi E, et al. Psychological, behavioral and biochemical risk factors for coronary artery disease among American and Italian male corporate managers. Am J Cardiol. 1992 Dec 1; 70(18):1412-6.
    View in: PubMed
  548. Renshaw PF, Guimaraes AR, Fava M, Rosenbaum JF, Pearlman JD, Flood JG, Puopolo PR, Clancy K, Gonzalez RG. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry. 1992 Nov; 149(11):1592-4.
    View in: PubMed
  549. Fava M, Rosenbaum JF, Cohen L, Reiter S, McCarthy M, Steingard R, Clancy K. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Affect Disord. 1992 Aug; 25(4):229-34.
    View in: PubMed
  550. Fava M, Rosenbaum JF, Birnbaum R, Kelly K, Otto MW, MacLaughlin R. The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand. 1992 Jul; 86(1):42-5.
    View in: PubMed
  551. Otto MW, Fava M, Rosenbaum JF, Murphy CF. Perceptual asymmetry, plasma cortisol, and response to treatment in depressed outpatients. Biol Psychiatry. 1991 Oct 1; 30(7):703-10.
    View in: PubMed
  552. Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship? J Clin Psychiatry. 1991 Mar; 52(3):108-11.
    View in: PubMed
  553. Fava M, Littman A, Halperin P, Pratt E, Drews FR, Oleshansky M, Knapik J, Thompson C, Bielenda C. Psychological and behavioral benefits of a stress/type A behavior reduction program for healthy middle-aged army officers. Psychosomatics. 1991; 32(3):337-42.
    View in: PubMed
  554. Fava M, Borofsky GF. Sexual disinhibition during treatment with a benzodiazepine: a case report. Int J Psychiatry Med. 1991; 21(1):99-104.
    View in: PubMed
  555. Fava M, Rosenbaum JF, McCarthy M, Pava J, Steingard R, Bless E. Anger attacks in depressed outpatients and their response to fluoxetine. Psychopharmacol Bull. 1991; 27(3):275-9.
    View in: PubMed
  556. Fava M, Anderson K, Rosenbaum JF. "Anger attacks": possible variants of panic and major depressive disorders. Am J Psychiatry. 1990 Jul; 147(7):867-70.
    View in: PubMed
  557. Rosenbaum JF, Fava M, Falk WE, Pollack MH, Cohen LS, Cohen BM, Zubenko GS. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand. 1990 May; 81(5):432-6.
    View in: PubMed
  558. Fava M, Rosenbaum JF, MacLaughlin R, Falk WE, Pollack MH, Cohen LS, Jones L, Pill L. Neuroendocrine effects of S-adenosyl-L-methionine, a novel putative antidepressant. J Psychiatr Res. 1990; 24(2):177-84.
    View in: PubMed
  559. Fava M, Copeland PM, Schweiger U, Herzog DB. Neurochemical abnormalities of anorexia nervosa and bulimia nervosa. Am J Psychiatry. 1989 Aug; 146(8):963-71.
    View in: PubMed
  560. Fava M, Rosenbaum JF, MacLaughlin RA, Tesar GE, Pollack MH, Cohen LS, Hirsch M. Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder. Psychiatry Res. 1989 Jun; 28(3):345-50.
    View in: PubMed
  561. Fava M, Guaraldi GP, Borofsky GL, Mastrogiacomo I. Childhood's enuresis in the history of women with hyperprolactinemic amenorrhea. Int J Psychiatry Med. 1989; 19(1):41-6.
    View in: PubMed
  562. Fava M, Serafini E, De Besi L, Adami A, Mastrogiacomo I. Hyperprolactinemia and psychological distress in women undergoing chronic hemodialysis. Psychother Psychosom. 1988; 49(1):6-9.
    View in: PubMed
  563. Fava M, Littman A, Halperin P. Neuroendocrine correlates of the type A behavior pattern: a review and new hypotheses. Int J Psychiatry Med. 1987; 17(4):289-307.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Fava's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_